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"Geographical Morality" Revisited:
International Relations, International Law,
and the Controversy over Placebo-Controlled
HIV Clinical Trials in Developing Countries
David P. Fidler*
I. INTRODUCTION
Since the early 1980s, the human immunodeficiency virus (HIV) and the
acquired immunodeficiency syndrome (AIDS) have wreaked enormous dam-
age on humanity.1 Table 1 below provides a statistical summary of the
enormous scale of the HIV/AIDS pandemic in the period from 1998 to
2000. No abatement of the horror of HIV/AIDS is on the horizon.
2
HIV/AIDS initially gained attention as an epidemic in developed countries,
but today 95% of existing cases are located in developing countries. 3 Sub-
Saharan Africa has been the most severely affected region in the world,4 but
* Professor of Law, Indiana University School of Law-Bloomington; M.Phil., University of Oxford,
1988; J.D., Harvard Law School, 1991; B.C.L., University of Oxford, 1991. 1 would like to thank Leslie
E. Schafer for her research assistance during the preparation of this Article. I owe Mary Ann Torres a debt
of gratitude in connection with this Article. I also thank my colleagues Roger Dworkin and Susan Wil-
hams for sharing their thoughts with me on aspects of this analysis.
1. See UNAIDS, REPORT ON THE GLOBAL HIV/AIDS EPIDEMIC: JUNE 2000, at 8 (2000), http://
www.unaids.org/epidemic4-updare/Epi-report.pdf (visited Mar. 15, 2001) (noting that "AIDS can devas-
tate whole regions, knock decades off national development, widen the gulf between rich and poor na-
tions and push already-stigmatized groups closer to the margins of society").
2. See id. (arguing that "unless action against the epidemic is scaled up drastically, the damage already
done will seem minor compared with what lies ahead").
3. See UNAIDS, AIDS EPIDEMIC UPDATE: DECEMBER 1998, at 2 (1998), http:/www.unaids.orgl
publications/documens/epidemiology/surveillancelwad1998/wadr983.pdf (visited Mar. 15, 2001).
4. See UNAIDS, REPORT ON THE GLOBAL HIV/AIDS EPIDEMIC: JUNE 2000, supra note 1, at 6 (pro-
viding statistics indicating that approximately 71% of all HIV/AIDS cases in 1999 lived in sub-Saharan
Africa); UNAIDS, AIDS EPIDEMIC UPDATE: DECEMBER 2000, at 11 (2000), http://www.unaids.orglwac/
2000/wadOO/fils[WAD..epidemicreport.htm (visited Mar. 15, 2001) ("Africa is home to 70% of the
adults and 80% of the children living with HIV in the world, and has buried three quarters of the more
than 20 million people worldwide who have died of AIDS since the epidemic began."); African AIDS
Crun Is Still Largely Ignored, REUTERS MEDICAL NEws, Feb. 5, 2001, http://www.reutershealth.com/
frame2/eline.html (visited Mar. 15, 2001) (quoting Dr. Kevin de Cock of the Centers for Disease Control
and Prevention in Atlanta, Georgia, who argued that "AIDS is undoubtedly Africa's biggest social catas-
trophe since the slave trade"); see also Johanna McGeary, Death Stalks a Continent, TIME, Feb. 12, 2001, at
36 (reporting on the African AIDS crisis).
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experts fear the further spread of HIV/AIDS in the huge populations of In-
dia and China.5
TABLE 1: SUMMARY OF THE HIV/AIDS PANDEMIC, 1998-20006
Category 1998 1999 2000
New HIV infections 5.8 million 5.4 million 5.3 million
People living with 33.4 million 34.3 million 36.1 million
HIV/AIDS
Deaths from AIDS 2.5 million 2.8 million 3.0 million
Total AIDS deaths 13.9 million 18.8 million 21.8 million
since beginning of
pandemic
Although HIV/AIDS is gaining prominence on the agendas of interna-
tional organizations7 and the great powers of the international system, 8 the
developing-country context of the pandemic creates significant problems in
international relations.9 One of the most acrimonious conflicts concerns the
5. See generally UNAIDS, REPORT ON THE GLOBAL HIV/AIDS EPIDEMIC: JUNE 2000, spra note 1, at
12 ("China and India between them account for around 36% of the world's population. With such huge
populations, even low HIV prevalence rates mean that huge numbers of people live with the virus.").
6. The data used to construct this table were taken from UNAIDS, AIDS EPIDEMIC UPDATE: DI3-
CEMBER 1998, supra note 3, at 1; UNAIDS, REPORT ON THE GLOBAL HIV/AIDS EPIDEMIC: JUNE
2000, supra note 1, at 6; UNAIDS, AIDS EPIDEMIC UPDATE: DECEMBER 2000, supra note 4, at 3.
7. For example, the United Nations Security Council held a special meeting in January 2000 to con-
sider the threat of political instability in Africa caused by HIV/ADS. This was the first Security Council
meeting ever that focused on a public health issue. See, e.g., Press Release, UNAIDS, AIDS Becoming
Africa's Top Security Issue, UN Warns: Devastating Epidemic Threatens Social and Political Stability
(Jan. 10, 2000), http://www.unaids.org/whatsnewlpresslenglpressarcOO/nylOlOO.html (visited Mar. 15,
2001); see also S.C. Res. 1308, U.N. SCOR, 4172d mtg. at 2, U.N. Doc. S/RES/1308 (2000) (expressing
"concern at the potential damaging impact of HIV/AIDS on the health of international peacekeeping
personnel"). The United Nations General Assembly also scheduled a special session on HIV/AIDS to be
held in June 2001. See Review of the Problem of Human Immunodeiciency ViruslAcquired Immunodeficiency Syn-
drome in All Its Aspects, G.A. Res. 283, U.N. GAOR, 54th Sess., Agenda Item 176, U.N. Doc.
A/RES/54/283 (2000); Review of the Problem of Human Immunodeficiency Virus/Acquired Immunodeficiency
Syndrome in All Its Aspects, G.A. Res. 13, U.N. GAOR, 55th Sess., Agenda Item 179, U.N. Doc.
A/RES/55/13 (2000); Special Session of the General Assembly on HIV/AIDS: Report of the Secretary-General,
U.N. GAOR, 55th Sess., Agenda Item 179, U.N. Doc. A/55/779 (2001) [hereinafter Report of the Secre-
tary-Generalj.
8. See, eg., G8 Kyushu-Okinawa Summit Meeting 2000, G8 Communiqu6 Okinawa 2000 29 (July
23, 2000), http:llwww.g8kyushu-okinawa.go.jple/documents/commu.htrml (visited Mar. 15, 2001) (commit-
ting G8 countries to help developing countries reduce the number of HIV/AIDS-infected young people
by 25% by 2010).
9. For many, HIV/AIDS has become not only a global health problem, but also an economic develop-
ment crisis because of the socio-economic impact HIV/AIDS is having in developing countries, especially
those in sub-Saharan Africa. In February 2001, the UN Secretary-General argued that
[a]cquired immunodeficiency syndrome (AIDS) has become a major development crisis.... In the
hardest hit regions, AIDS is now reversing decades of development .... By eventually impairing
economic growth, the epidemic has an impact on investment, trade and national security, leading to
2001 / Placebo-Controlled HIV Clinical Trials
lack of affordable access to effective HIV therapies in developing countries. 10
Antiretroviral therapies, such as zidovudine (AZT) and protease inhibitors,
have allowed persons with HIV living in developed countries to avoid ac-
quiring AIDS and live longer lives," but the therapies are expensive even in
affluent countries and have been unaffordable to most individuals suffering
from HIV/AIDS in developing countries. 12
Three strategies have emerged to address the problem that HIV therapies
are not affordable in developing countries. The first involves Western phar-
maceutical companies reducing prices on HIV therapies to help make devel-
oping-country access more realistic. 13 The second strategy is for govern-
ments in developing countries to use compulsory licenses to allow cheaper
production of HIV therapies in their jurisdictions. 14 The third strategy is to
develop HIV vaccines and new HIV therapies and therapy regimens that are
less expensive and easier to implement than existing treatments. 15 This third
still more widespread and extreme poverty. In short, AIDS has become a major challenge for human
security.
Report of the Secretary-General, supra note 7, at 4, 6.
10. See UNAIDS, REPORT ON THE GLOBAL HIV/AIDS EPIDEMIC: JUNE 2000, supra note 1, at 99
(noting that the cost of drugs is one underlying reason for the poor access in developing countries).
11. See UNAIDS, Accelerating Access to HIV Care. Support and Treatment News Bulletin Number 1, Nov.
15, 2000, http://www.unaids.org/accaccess/acc_care_support/newsjbulletin.html (visited Mar. 15,
2001) (noting that "'medical care in industrialized countries is significantly extending the lives of people
living with HIV").
12 Hope, ECONOMIST, June 29, 1996, at 84 (noting that new HIV therapy regimens cost between
$10,000 and $12,000 annually and arguing that "[alt this price it will be of precious little use to more
than 90% of those people infected with the virus-the ones who live in poor countries").
13 UNAIDS, REPORT ON THE GLOBAL HIV/AIDS EPIDEMIC: JUNE 2000, supra note 1, at 100 (dis-
cussing price reductions for antiretroviral drugs for use in developing countries); UNAIDS, Accelerating
Access to HIV Care. Support and Treatment Neus Bulletin Number 2, Feb. 20, 2001, http://www.unaids.orgl
acc_access/acccare..support/news.bulletin2.html (visited Mar. 15, 2001) (noting that tiered pricing of
HIV-related medicines where pharmaceutical companies make such medicines available to developing
countries at highly reduced prices constitutes one strategy to increase access, and reporting on agree-
ments reached between Rwanda, Senegal, and Uganda to buy HIV therapies at significantly reduced
prices from pharmaceutical companies).
14. UNAIDS, REPORT ON THE GLOBAL HIV/AIDS EPIDEMIC: JUNE 2000, supra note 1, at 102-03
(discussing compulsory licensing in connection with HIV/AIDS drugs); Tina Rosenberg, Look at Brazil,
N.Y TIMES, Jan. 28, 2001 (magazine), at F26 (reporting on Brazil's successful use of compulsory licens-
ing in producing cheap generic HIV therapies and distributing them freely and widely to Brazilians
living with HIV); Donald G. McNeil, Jr., Indian Company Offers to Supply AIDS Drugs at Low Cost in
Africa, N.Y TIMES, Feb. 7, 2001, at Al (reporting on Indian pharmaceutical company's offer to sell HIV
therapies at a price far below that offered by Western pharmaceutical companies); Press Release, Mide-
cins Sans Frontijres, AIDS Triple Therapy for Less than $I a Day-MSF Challenges Pharmaceutical
Industry to Match Generic Prices, Feb. 7, 2001, http://www.accessmed.msf.org (visited Mar. 15, 2001)
(encouraging developing countries to "take full advantage of their rights to produce or import generic
AIDS drugs under the [World Trade Organization (WTO) Agreement on Trade-Related Aspects of In-
tellectual Property Rights (TRIPS)]").
15 On therapies, see Peter Lurie & Sidney M. Wolfe, Unethical Trials ofinterventions to Reduce Perinatal
Traasmoson of the Human Immunodeficien0 Virus in Developing Countries, 337 NEw ENG. J. MED. 853, 853
(1997) (noting the need for less expensive HIV therapies in both developing and developed countries).
On vaccines, see International AIDS Vaccine Initiative, The World Needs an AIDS Vaccine, htrp:/l
www.iavi.org/vaccine_zworld.html (visited Mar. 3, 2001):
Prevention programs-including education, condom and clean needle distribution and peer coun-
seling-have slowed the spread of HIV, but have not stopped it. Treatment advances have yielded
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strategy requires researchers to conduct clinical trials to test the efficacy of
vaccines, new drugs, or new drug regimens. Developing countries have been
and will continue to be an attractive venue for such clinical trial research.
Each of these strategies has proven controversial. The reduction of prices
by Western pharmaceutical companies has not significantly improved access
to HIV therapies in developing countries. 16 The attempted use of compul-
sory licenses by governments in developing countries sparked conflict be-
tween such governments, Western pharmaceutical companies, and the
United States. 17 The conduct of HIV/AIDS clinical trial research in devel-
important new AIDS therapies, but the cost and complexity of their use put them out of reach for
most people in the countries where they are needed the most. In industrialized nations where drugs
are more readily available, side effects and increased rates of viral resistance have raised concerns
about their long-term use. Only an AIDS vaccine can end the HIV/AIDS pandemic.
16. UNAIDS, REPORT ON THE GLOBAL HIV/AIDS EPIDEMIC: JUNE 2000, stpra note 1, at 103
(noting that "pharmaceutical companies have not yet decreased their prices enough to make their prod-
ucts affordable to the majority of people in developing countries"). In May 2000, five major pharmaceuti-
cal companies signed ajoint Statement ofIntent with the United Nations pledging to sell HIV therapies
at lower cost to developing countries. Michael Waldolz, Into Africa: Makers of AIDS Drugs Agree to Slash
Prices for Developing World, WALL ST. J., May 11, 2000 at Al. The drug prices under this agreement
would still not be affordable for most populations in Africa. Id. In April 2001, UN Secretary-General
Kofi Annan announced a new agreement with six major pharmaceutical companies under which the
companies agreed to continue cutting the prices of HIV/AIDS drugs for developing nations. Companies
Promise More AIDS-Related Drug Price Cuts For Poor, REUTERS MEDICAL NEws, Apr. 5, 2001,
http://www.medscape.com/ reuters/prof/200104104.06120010405publOO6.html (visited Apr. 20, 2001).
Under the new agreement, the pharmaceutical companies will offer HIV/AIDS drugs to the least devel-
oped countries as a group and continue to reduce prices for other developing countries on a country-by-
country basis. Id. See also Press Release, UNAIDS, Statement by the UN Secretary-General After Meeting
the Leaders of Six Leading Research-Based Pharmaceutical Companies (Apr. 5, 2001), http://www.unaids.
orglwhatsnevlpress/eng/pressarcOllSgstate_050401.html (visited Apr. 22, 2001). Pricing of HIV/AIDS
drugs also featured prominently at an April 2001 conference of experts jointly sponsored by the World
Trade Organization (WTO) and the World Health Organization (WHO) on access to essential drugs at
which consensus emerged for "differential pricing" as a means of achieving greater access for developing
countries. See Press Release, WTO, Experts: Affordable Medicines for Poor Countries Feasible, WTO
Doc. Press/220 (Apr. 11, 2001), http:l/www.wto.org/english/newse/pres0le/pr220_e.htm (visited Apr.
22, 2001). The lawsuit by thirty-nine pharmaceutical companies against South Africa in South African
courts challenging legislation that contains the power to use compulsory licensing and parallel importing
to increase access to essential drugs has, however, caused intense and acrimonious controversy in the area
of increasing access to HIV/AIDS drugs. See, e.g., Press Release, Mdecins Sans Frontires/Oxfam, 39
Drug Companies versus South Africa: People Die for Lack of Affordable Drugs as Inhumane Industry
Ignores Reality (Mar. 5, 2001), http:llwww.accessmed-msf.org/msflaccessmedlaccessmed2.nsf/46c19
fd02103f27ec1256871005db296ffSaddbbaedld35d4l256a60039eb9?OpenDocument (visited Apr.
22, 2001) (calling the lawsuit by the pharmaceutical companies "one of the most stark acts of corporate
inhumanity"). On April 19, 2001, the thirty-nine pharmaceutical companies dropped their lawsuit
against South Africa. Non-governmental organizations that had been criticizing the pharmaceutical
companies claimed that global public opinion had forced the companies to drop the suit. See Press Re-
lease, M~decins Sans Fronti res/Oxfam/Treatment Action Group, Drug Companies in South Africa Ca-
pitulate Under Barrage of Public Pressure: Powerful Precedent Set for Other Developing Countries (Apr.
19, 2001), http::/www.accessmed-msf.org/msf/accessmed/accessmed2.nsf/46c19fd02103f27ec1256871005
db296/dff999938c5bcl18c1256a33004467f6?OpenDocument (visited Apr. 22, 2001) ("In response to
resounding global denunciation of their lawsuit, 39 drug companies today unconditionally dropped the
case they pursued for three years against the South African government. The end of the lawsuit clears the
path for the 1997 Medicines Act to go into force, allowing importation of affordable medicines and
increased use of quality generic drugs.").
17. The United States has been engaged in a series of disputes with developing countries over in-
creasing access to drugs through compulsory licensing and parallel importing. Details of the disputes can
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oping countries by researchers from developed countries has brought forth
charges of unethical behavior on the part of, and exploitation by, Western
researchers. 18 This Article focuses on these provocative ethical charges.
Part II describes the HIV clinical trials that triggered one of the most ac-
rimonious controversies in the history of clinical research ethics. 19 The clini-
cal trials in question sought to ascertain whether a short-course regimen of
AZT would reduce perinatal, or mother-to-child, transmission of HIV.20
Previous research showed that a longer-course AZT regimen reduced perina-
tal HIV transmission rates, but such a long-course AZT treatment was un-
affordable and impractical to implement in most developing countries.2 1
Western researchers, funded by developed-country governments, designed
the perinatal HIV transmission clinical trials to test the short-course AZT
regimen against a placebo, which meant that some of the research subjects
received the short course of AZT while the rest received no therapy at all.22
Critics attacked the use of the placebo in the clinical trials as unethical. 23 A
significant feature of the criticism was the accusation that the researchers
and their sponsoring governments adopted an ethical "double standard": the
use of the placebo in such a clinical trial would never have been allowed in a
developed country because of ethical principles.2 4
Critics of the placebo-controlled clinical trials often employ the language
of human rights to attack the ethics of the trials.25 The use of human rights
concepts and arguments brings international law into the debate. The con-
troversy has, to date, not involved much input from international lawyers. 26
be found at the following Web sites of the Consumer Project on Technology: http://www.cptech.orglip/
health/sa/ (South Africa), http:/www.cptech.org/ip/healthlc/thailand (Thailand), http://www.cptech.org/
ip/health/c/dr/ (Dominican Republic), and http://www.cptech.org/ip/ health/c/brazil/ (Brazil) (all visited
Mar. 3, 2001).
18. See Lurie & Wolfe, supra note 15, at 853 (articulating the most famous accusation that certain HIV
clinical trials were unethical).
19. See Douglas P Lackey, Clinical Trials in Developing Countries: A Review of the Moral Issues, 68
MOUNT SINAI J. MED. 4, 4 (2001) (noting that Lurie and Wolfe's accusations in the New EnglandJournal
ofMadcne in September 1997 "exploded like a bombshell over the medical ethics community. Not since
Henry Beecher's assault in 1966 on the ethics of clinical research scientists had such accusations been
hurled about on those cream-colored pages" (footnote omitted)).
20. See infra Part II.A.
21. Seeid.
22. Se id.
23. See infra Part II.B.
24. See id.
25. See, e.g., George J. Annas & Michael A. Grodin, Human Rights and Maternal-Fetal HIV Transmission
Prewntion Trials in Africa, 88 Am. J. PUBLIc HEALTH 560, 560 (1998) (stressing the importance of the
Universal Declaration of Human Rights to challenges mounted against the placebo-controlled trials);
Troyen A. Brennan, Proposed Revisions to the Declaration of Helsinki-Will They Weaken the Ethical Principles
Underlying Human Research?, 341 NEw ENG. J. MED. 527, 528-29 (1999) (arguing that proposed revi-
sions to the Declaration of Helsinki undermine the protection of individual rights).
26. Lawyers have been a part of the discourse. George J. Annas, who is a professor of health law, has
been prominent in the debate. See Annas & Grodin, supra note 25, at 560. In addition, Global Lawyers
and Physicians, a non-governmental organization that promotes the health-related provisions of the
Universal Declaration of Human Rights, joined Public Citizen in attacking the placebo-controlled trials.
Id. This controversy has nor, however, attracted much attention in the mainstream community of inter-
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This Article analyzes the ethical controversy over the placebo-controlled
trials through the lens of international law, adding a new dimension to the
developing discourse on this important global issue.
Two central ethical questions emerge from the controversy over the pla-
cebo-controlled clinical trials. The first question is whether ethical research
practices (1) require an international standard of care that applies universally
to all countries and peoples; or (2) allow clinical trial design and implemen-
tation to take into account the local standards of care. 27 The second question
is whether clinical trials conducted in developing countries involve exploita-
tion when the fruits of such trials are unlikely to benefit the people in those
countries in the short- or long-term. 28 Critics of the placebo-controlled trials
have argued that the trials were unethical because they violated the human
rights of pregnant women who participated in the trials and the children
born to them. 29 A deeper human rights claim is implicit in these arguments
because international ethical guidelines, such as the Nuremberg Code,30 the
Declaration of Helsinki,31 and the Guidelines of the Council for Interna-
tional Organizations of Medical Sciences ("CIOMS Guidelines")32 rest on a
foundation of respect for fundamental human rights. 33
national law. For an exception, see Jonathan Todres, Can Research Subjects of Clinical Trials in Developing
Countries Sue Physician-Investigators for Human Rights Violations?, 16 N.Y.L. ScH. J. HUM. RTs. 737 (2000)
(analyzing whether the research subjects of the placebo-controlled clinical trials can sue the researchers in
U.S. courts under the Alien Tort Claims Act for violations of international law).
27. See Lurie & Wolfe, supra note 15, at 855 (raising the issue of double standards and arguing that
"[ilt is time to develop standards of research that preclude the kinds of double standards evident in these
trials").
28. See Annas & Grodin, supra note 25, at 561 ("The central issue involved in doing research with im-
poverished populations is exploitation.").
29. Letter from Peter Lurie, Research Associate, Public Citizen; Sidney M. Wolfe, Director, Public
Citizen's Health Research Group; George Annas, Professor of Health Law, Boston University School of
Public Health, Co-founder, Global Lawyers and Physicians: Working Together for Human Rights [here-
inafter Global Lawyers & Physicians]; Michael A. Grodin, Professor of Medical Ethics, Boston University
School of Public Health, Co-founder, Global Lawyers & Physicians; and George Silver, Emeritus Professor
of Medicine, Yale University School of Medicine, to Donna Shalala, Secretary of the U.S. Department of
Health and Human Services (Apr. 22, 1997), http:llwww.citizen.org/hrg/publications/1415.htm (visited
Mar. 15, 2001) [hereinafter Letter to Secretary Shalala] (arguing that because of the placebo-controlled
trials "1,504 infants... can be expected to die unnecessarily in these experiments"); Lurie & Wolfe, stpra
note 15, at 853 (arguing that HIV-positive pregnant women participating in the placebo-controlled trials
were denied treatment available to HIV-pregnanr women in clinical trials in developed countries); Annas
& Grodin, supra note 25, at 560 (stressing the application of the Universal Declaration of Human Rights
to HIV-transmission prevention trials in Africa).
30. See Nuremberg Code, in 2 NUREMBERG MILITARY TRIBUNALS, TRIALS OF THE WAR CRIMINALS
BEFORE THE NUREMBERG MILITARY TRIBUNALS UNDER CONTROL COUNCIL LAw No. 10, NUREM-
BERG, OCTOBER 1946-OcrOBER 1949, at 181-82 (1949).
31. World Med. Ass'n, Declaration of Helsinki, adopted by the 18th WMA General Assembly, Hel-
sinki, Finland, June 1964, and as amended by the 48th WMA General Assembly, Somerset West, South
Africa, October 1996 [hereinafter Declaration of Helsinki (1996)]. The Declaration of Helsinki was
amended further in 2000, see infra text accompanying note 72.
32. COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES, INTERNATIONAl, ETHI-
CAL GUIDELINES FOR BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (1993) [hereinafter CIOMS
GUIDELINES].
33. See Jonathan Mann, Medicine and Public Health, Ethics and Human Rights, 27 HASTINGS CENTER
REP. 6, 10 (1997) (arguing that "rather than seeing human rights and ethics as conflicting domains, it
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These two ethical arguments raise interesting questions for an interna-
tional lawyer. If the placebo-controlled trials violated human rights, then
exactly what rights were violated, and how were they violated? Does inter-
national law recognize a human right to receive the best care available any-
where in the world when a person participates in a clinical trial? Does inter-
national law require governments sponsoring international clinical trials to
make successful drugs and vaccines available at affordable prices in countries
in which the clinical research takes place? Answering these questions in-
volves analysis of relevant human rights as they are embedded in interna-
tional law. While this analysis is legal in orientation, it bears on and informs
the ethical debate.
Ethical concerns about exploitation and international versus local stan-
dards of behavior are familiar to those who study international relations and
international law. In fact, these ethical issues connect with long-standing
controversies in international relations and international legal theory. Differ-
ent approaches to explaining international relations and international law
take distinct and sometimes antithetical positions on the role and impor-
tance of ethics and law in international politics and economics. 34 While this
larger realm may seem distant from ethical arguments about the placebo-
controlled trials, it is important because how we view international ethical
standards and international law flows from how we perceive the nature of
international relations. The relevance of international relations theory can be
seen in the arguments of some experts that the furor over the placebo-
controlled trials underscores the fundamental injustice of the world political
and economic order.35 Behind the scientific, medical, public health, ethical,
and international legal discourses on the placebo-controlled trials are dis-
agreements about how power is distributed, regulated, and exercised in in-
ternational relations.
This analysis proceeds in three parts. Part III looks at the problem of ethi-
cal "double standards" and the exploitation they foster from the perspective
of international relations theory. It frames the international relations analysis
around Edmund Burke's attack on the concept of "geographical morality"-
seems more appropriate to consider a continuum, in which human rights is a language most useful for
guiding societal level of analysis and work, while ethics is a language most useful for guiding individual
behavior").
34. See, e.g., TERRY NARDIN, LAW, MORALITY, AND THE RELATIONS OF STATES (1983); TRADITIONS
OF INTERNATIONAL ETHICS (Terry Nardin & David R. Mapel eds., 1992).
35. See Annas & Grodin, supra note 25, at 562 (arguing that developed countries must take economic,
cultural, and social rights as seriously as civil and political rights in tackling public health problems in
poor countries); Robert J. Levine, The Need to Revise the Declaration of Helsinki, 341 NEw ENG. J. MED.
531, 534 (1999) (noting the need "to acknowledge with regret that there are great imbalances in the
distribution of wealth among nations of the world"); Ronald Bayer, The Debate Over Maternal-Fetal HIV
Tranmission Preiention Trials in Africa, Asia, and the Caribbean: Racist Exploitation or Exploitation of Racism,
88 AM. J. pun. HEALTH 567, 570 (1998) ("The tragedy of the recent trials is that they bear a profound
moral taint ... of a world economic order that makes effective prophylaxis for the interruption of mater-
nal-fetal HIV transmission available but unaffordable for many .... In a just world, this would not be
the case. .... ").
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the idea that moral standards vary in different geographical regions of the
world. 36 Burke confronted the "geographical morality" problem in his ef-
forts to improve British imperial practices in India, but his analysis of this
problem sets up broader debates in international relations theory about the
role of ethics and international law.37 The ethical debate about the placebo-
controlled trials assumes that ethics are important in the conduct of interna-
tional relations. An international legal analysis of the placebo-controlled
trials likewise assumes that international law is important in international
relations. Part III's analysis demonstrates that both of those assumptions are
controversial in international relations theory. Understanding these contro-
versies in the study of international relations helps put the ethical and inter-
national legal aspects of the debate over the placebo-controlled trials into
theoretical perspective.
Part IV analyzes whether the placebo-controlled trials violated interna-
tional human rights law. The analysis covers both civil and political human
rights and economic, social, and cultural rights, and concludes that the pla-
cebo-controlled trials did not involve violations of international human
rights law. In addition, the analysis suggests that international human rights
law does not presently condemn ethical double standards in contexts such as
the placebo-controlled trials. Moreover, in the area of economic, social, and
cultural rights, the international legal principles work against the estab-
lishment of universally applicable standards.
Part V concludes by reflecting on the implications of the analysis in Parts
III and IV for the ethical dispute over the placebo-controlled trials. It
sketches out three different paths for dealing with the ethical problems cre-
ated by the placebo-controlled trials and the importance of the international
legal analysis for choosing a path to take.
II. THE CONTROVERSY OVER THE PLACEBO-CONTROLLED
HIV CLINICAL TRIALS
A. Background Information on the Placebo-Controlled HIV Trials
The clinical trials at the center of the ethical storm that emerged in Sep-
tember 1997 represented attempts by researchers and governments in devel-
oped and developing countries to find a more affordable and practical way to
administer AZT to pregnant women living with HIV in developing coun-
tries in order to reduce perinatal HIV transmission. With millions of HIV-
infected women in developing countries giving birth every year, reducing
perinatal HIV transmission became an important public health goal in the
fight to control the HIV/AIDS pandemic.38 UNAIDS reported in June 2000
36. See infra Part II.A.
37. See infra Part III.B.
38. See UNAIDS, REPORT ON THE GLOBAL HIV/AIDS EPIDEMIC: JUNE 2000, supra note 1, at 81
(reporting that the vast majority of the 3.8 million children who have died of AIDS before their fifteenth
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that "[the developing world, and especially sub-Saharan Africa, stands to
gain even more from large-scale programmes for reducing mother-to-child
transmission because women [in developing countries] have more children
and have far higher rates of HIV infection."
39
Prior research demonstrated that an AZT therapy regime known as the
"076 regimen" 40 reduced rates of HIV transmission from infected, pregnant
women to their infants. The 076 regimen involved treating HIV-infected
pregnant women with AZT for up to twenty-six weeks during pregnancy
and during labor and childbirth.41 The 076 regimen also involved providing
infants of HIV-positive mothers with AZT for six weeks after birth.4 2 While
the 076 regimen proved effective in clinical trials in reducing perinatal HIV
transmission, 43 the length and intensity of the regimen were beyond the
financial and public health capabilities of many developing countries.
44
HIV/AIDS researchers in the United States and Europe designed clinical
trials to take place in developing countries to test the efficacy of less expen-
sive and complex interventions, such as a short-course use of AZT, in re-
ducing perinatal transmission of HIV.45 In these clinical trials, researchers
gave one group of HIV-positive pregnant women a shortened course of AZT
that covered the last month of pregnancy and the process of childbirth.
46
The researchers gave a second group of HIV-positive pregnant women place-
bos or no therapy at all.47 The results from the women receiving the short-
course AZT regimen were evaluated against the control group of women
receiving placebos to determine how effective the short-course AZT regimen
was in reducing perinatal HIV transmission.
The United States sponsored nine such placebo-controlled clinical trials,
and six more were sponsored by France (two studies), Belgium, Denmark,
South Africa, and UNAIDS. 48 C~te d'Ivoire, Uganda, Tanzania, South Af-
birthday and of the 1.3 million children who are currently living with HIV "were born to HIV-infected
mothers; they acquired the virus in the womb, around the time of childbirth or during breastfeeding").
39 Id
40. This regimen takes its name from Pediatric AIDS Clinical Trials Group (ACTG) Protocol 076
Study, which was the first clinical trial to show the effectiveness of an AZT regimen in reducing perinatal
HIV transmission. See Edward M. Connor et al., Reduaion of Maternal-Infant Transmission of Human Imma-
nodifwiency Virus Type I uith Zidoudne Treatment, 331 NEw ENG. J. MED. 1173 (1994).
41 Id. at 1175 (reporting that the women in the clinical trial testing the 076 regimen received the
AZT regimen for a median of eleven weeks, with zero to twenty-six weeks being the range of treatment).
42. Id. at 1174 (reporting that infants were given AZT orally every six hours for six weeks).
43 Id. at 1178 ("Our study indicates that substantial reduction in the rate of maternal-infant trans-
misslon of HIV is possible [with the 076 regimen of AZT] with minimal short-term toxicity to mother
or child.").
44. See UNAIDS, REPORT ON THE GLOBAL HIV/AIDS PANDEMIC: JUNE 2000, supra note 1, at 81
(noting that -the drug regimens used in high-income countries for reducing HIV transmission to infants
are too expensive and complicated to be practical for wide-scale use in poor countries"); Lurie & Wolfe,
supra note 15, at 853 (noting that "the potential of the ACTG 076 regimen remains unrealized primarily
because of the drug's exorbitant cost in most countries").
45 See Lurie & Wolfe, supra note 15, at 853.
46. Todres, supra note 26, at 738.
47. Id.
48. See Letter to Secretary Shalala, supra note 29.
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rica, Malawi, Thailand, Ethiopia, Burkina Faso, Zimbabwe, Kenya, and the
Dominican Republic hosted the placebo-controlled trials. 49 Scientists and
physicians from the host countries also participated in the research con-
ducted in the placebo-controlled trials. 50 Both the sponsoring and host
countries reviewed the research protocols for the placebo-controlled trials for
scientific validity and conformity with prevailing ethical standards on con-
ducting medical research on human subjects.51
B. An Ethical Controversy Erupts Concerning the Placebo-Controlled Trials
In September 1997, Peter Lurie and Sidney Wolfe of the advocacy group
Public Citizen criticized these placebo-controlled clinical trials as unethical
and exploitative. 52 Lurie and Wolfe argued that giving the women in the
control group placebos rather than the 076 regimen was unethical because it
denied these women the standard of care available to clinical trial partici-
pants in developed countries. 53 The World Medical Association's Declaration
of Helsinki (1996)-one of the most important documents guiding the
ethics of biomedical research-provided in 1996 that "[i]n any medical
study, every patient-including those of a control group, if any-should be
assured of the best proven diagnostic and therapeutic method." 54 In the case
of perinatal transmission of HIV, the 076 regimen of AZT was the best-
proven therapeutic method. Lurie and Wolfe argued that, if the clinical tri-
als in question had taken place in a developed country, the control group
would have received AZT antiretroviral treatment and not placebos since
giving placebos would have, without question, been considered unethical
because it denied the women the best available standard of care. 55 The re-
searchers running the placebo-controlled trials had, in short, created a dou-
ble ethical standard for clinical trial research: a higher ethical standard for
49. Lurie & Wolfe, supra note 15, at 853.
50. See Harold Varinus & David Satcher, Ethical Complexities ofConducting Research in Developing Coun-
tries, 337 NEw ENG. J. MED. 1003, 1005 (1997).
51. See id.
52. Lurie & Wolfe, supra note 15, at 853. One of the editors of the New England Journal of Medicine
supported the accusations of Lurie and Wolfe. See Marcia Angell, The Ethics of Clinical Research in the Third
World, 337 NEW ENG. J. MaD. 847 (1997); Marcia Angell et al., AIDS Studies Violate Helsinki Rights
Accord, N.Y. TiFs, Sept. 24, 1997, at A26. Lurie and Wolfe have been the leading critics of the placebo-
controlled trials, and this Article focuses on their sustained campaign to expose the unethical nature of
the trials and to encourage the adoption of a universal standard that would ensure all subjects of medical
research the highest standard of care available. Lurie and Wolfe's efforts triggered an international con-
troversy that is reflected not only in the many other sources cited in this Article but also in the revision of
important international documents on the ethics of scientific research involving human subjects. See infra
text accompanying notes 63-72.
53. Lurie & Wolfe, supra note 15, at 855.
54. Declaration of Helsinki (1996), supra note 31, princ. 11.3.
55. Lurie & Wolfe, supra note 15, at 853 (noting that in "two studies being performed in the United
States, the patients in all the study groups have unrestricted access to zidovudine or other antiretroviral
drugs"); Letter to Secretary Shalala, supra note 29 ("In essence, the U.S.-funded researchers are conducting
experiments abroad that would never pass ethical muster in the U.S.").
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people in developed countries and a lower ethical standard for people in de-
veloping countries.56
The directors of the U.S. National Institutes of Health (NIH) and Centers
for Disease Control and Prevention (CDC), Harold Varmus and David
Satcher, responded to Lurie and Wolfe's attack by defending the placebo-
controlled trials.57 They argued that Lurie and Wolfe offered a simplistic
perspective on conducting clinical trials in developing countries because
"they have not adequately considered the purpose and complexity of such
trials and the needs of the countries involved." 58 Varmus and Satcher claimed
that "[tihe most compelling reason to use a placebo-controlled study is that
it provides definitive answers to questions about the safety and value of an
intervention in the setting in which the study is performed, and these answers are
the point of the research."5 9 In other words, the ethics of the placebo-
controlled trials has to be evaluated with local conditions in mind, including
local standards of therapeutic care. Important to the NIH and CDC directors
was the 1994 recommendation by an international panel convened by the
World Health Organization that "placebo-controlled trials offer the best
option for obtaining rapid and scientifically valid results." 60 Varmus and
Satcher pointed out both the difficulty and exorbitant cost of the 076 regi-
men in most developing countries, suggesting that ethical evaluation of the
trials has to take into consideration the differences in public health and
health care resources between developed and developing countries. 61 The
directors of the agencies also pointed to the support and approval the pla-
cebo-controlled trials received from local physicians, researchers, and gov-
ernment officials in the developing countries involved. 62
56 Lurie & Wolfe, supra note 15, at 855 ("Acceptance of a standard of care that does not conform to
the standard in the sponsoring country results in a double standard in research."); Letter to Secretary
Shalala, supra note 29 ("For your department to maintain a double standard in which it funds studies that
on the one hand routinely provide life-saving drugs to Americans, while on the other deny these drugs to
thousands of citizens of developing countries, conveys to the international community the impression
that the U.S. government places less value on the lives of non-Americans.").
57. See Varmus & Satcher, supra note 50, at 1003; see also Nat'l Insts. of Health & Ctrs. for Disease
Control and Prevention, The Conduct of Clinical Trials of Maternal-Infant Transmission of HIV Supported by
the United States Department of Health and Human Services in Developing Countries: A Summary of the Needs of
DetWoping Countries, the Scientific Applications, and the Ethical Considerations Assessed by the National Institutes
of Health and the Centers for Disease Control and Prevention, 1994-1997 (July 1997), http:llwww.nih.gov/
news/mathiv/mathiv.htm (visited Mar. 5, 2001) [hereinafter NIH/CDC Document].
58. Varmus & Satcher, supra note 50, at 1003.
59. Id at 1004 (emphasis added).
60. WHO, Recommendations from the Meeting on Prevention of Mother-to-Infant Transmission of
HIV by Use of Antiretrovirals, Geneva, Switzerland (June 23-25, 1994), http://www.nih.govlnews/
mathiv/whodoc.htm (visited Mar. 5, 2001), Recommendation 6 [hereinafter WHO Panel Recommenda-
tions) For the importance of this recommendation to the NIH and CDC, see NIH/CDC Document,
supra note 57 (citing Recommendation 6).
61. Varmus & Satcher, supra note 50, at 1004; see also WHO Panel Recommendations, supra note 60
(stressing the ethical importance of local standards of care in the argument that in the developing world
"the choice of placebo for the control group of a randomized trial would be appropriate as there is cur-
rently no effective alternative for HIV-infected pregnant women").
62. Varmus & Satcher, supra note 50, at 1005.
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The battle between opponents and defenders of the ethics of placebo-
controlled trials continued as the World Medical Association and the Coun-
cil for International Organizations of Medical Sciences (CIOMS) began revi-
sions of their respective guidelines and principles on the ethics of biomedical
research. 63 In addition, the controversy over the placebo-controlled trials also
affected the drafting by UNAIDS of its Guidance Document on Ethical
Considerations in HIV Preventive Vaccine Research, eventually published in
May 2000 ("UNAIDS Guidance Document"). 64
In connection with the proposed revisions in March 1999 to the Declara-
tion of Helsinki (1996) by the World Medical Association, Lurie and Wolfe
expressed alarm at the draft amendments and attacked, among other pro-
posed modifications, changes to Principle 11.3 of the declaration that would
add the phrase "that would otherwise be available to him or her" to the duty
to give research subjects "the best proven diagnostic and therapeutic
method." 65 Lurie and Wolfe referred to this proposed change as an "insidious
assault on the rights of participants in research" that will condemn "most
residents in developing countries to potentially receiving second-rate medi-
cal care when they participate in experiments." 66 They also criticized the
proposed draft for greatly expanding the potential use of placebos in clinical
trials.67 Public Citizen complained that similar changes were being consid-
ered in revision of the CIOMS Guidelines and the proposed UNAIDS guid-
ance document for HIV vaccine trials.68 Wolfe argued that "[tjhese changes
would formalize double standards based on economics, convenience and
efficiency that should be anathema to any physician or patient."69
In connection with the drafting of the UNAIDS Guidance Document,
Lurie and Wolfe criticized the proposed document in January 1999 for,
among other things, proposing the standard of "highest attainable therapeu-
63. See Declaration of Helsinki (1996), supra note 31; CIOMS GUIDELINES, Supra note 32.
64. UNAIDS, ETHICAL CONSIDERATIONS IN HIV PREVENTIVE VACCINE RESEARCH: UNAIDS
GUIDANCE DOCUMENT (2000), http//www.unaids.org/publications/documents/vaccinesvaccineslEthics
research.pdf (visited Mar. 15, 2001) [hereinafter UNAIDS GUIDANCE DOCUMENT].
65. Letter from Peter Lurie & Sidney M. Wolfe, Public Citizen, to Dr. Delon Human, World Medical
Association (Mar. 29, 1999), http:llwww.cicizen.orglhrglpublications/1477.htm (visited Mar. 15, 2001)
[hereinafter Letter to Human (Mar. 29, 1999)]; see also Letter from Peter Lurie & Sidney M. Wolfe, Public
Citizen, to Dr. Delon Human, World Medical Association (July 31, 2000), http://www.citizen.org/hrgl
publications/1531.htm (visited Mar. 15, 2001) [hereinafter Letter to Human (July 31, 2000)].
66. Letter to Human (Mar. 29, 1999), supra note 65.
67. Id.
68. Press Release, Public Citizen, Scientists Seek to Justify and Continue Unethical Research by Gut-
ting International Ethical Guidelines (Aug. 11, 1999), http:lwww.citizen.org/press/pr-sid22.hrm (vis-
ited Mar. 15, 2001) [hereinafter Public Citizen Press Release Aug. 1999]; Letter from Peter Lurie &
Sidney M. Wolfe, Public Citizen, to Jose Esparza, UNAIDS (Jan. 15, 1999), http://www.citizen.org/hrg/
publications/1471.htm (visited Mar. 15, 2001) [hereinafter Letter to Esparza] (commenting that the
proposed changes to the Declaration of Helsinki and the CIOMS Guidelines and the proposed UNAIDS
Guidance Document would be "a weakening of protections for research subjects in developing countries,
opening them up to more exploitation as research increasingly becomes international"); Letter from Peter
Lurie & Sidney M. Wolfe, Public Citizen, to Peter Piot, Executive Director of UNAIDS (Feb. 11, 2000),
http://www.citizen.orglhrg/publications/1508.htm (visited Mar. 15, 2001).
69. Public Citizen Press Release Aug. 1999, supra note 68.
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tic method," which opens the door for lower standards of care to be justified
by the local conditions in developing countries.70 Lurie and Wolfe asserted
that the UNAIDS Guidance Document was being used "as a stalking horse
for revisions of the CIOMS document and the Declaration of Helsinki.
' 71
The final revised versions of the Declaration of Helsinki and the UNAIDS
Guidance Document have not calmed down the ethical storm Lurie and
Wolfe created with their accusations. The World Medical Association
adopted an amended version of the Declaration of Helsinki in October
2000.72 Principle 29 of the Declaration of Helsinki (2000) states that "[tlhe
benefits, risks, burdens and effectiveness of a new method should be tested
against those of the best current prophylactic, diagnostic, and therapeutic
methods."7 3 Principle 30 provides that "[alt the conclusion of the study,
every patient entered in the study should be assured of access to the best
proven prophylactic, diagnostic and therapeutic methods identified by the
study."7 4 Under Principle 29, the placebo-controlled trials Lurie and Wolfe
attacked would be unethical because the short-course AZT regimen was
tested against placebos, not against the 076 regimen. After earlier drafts of
the revised Declaration contained language that would have upheld the ethi-
cal basis for the placebo-controlled trials, the World Medical Association
moved in the final version toward the universal standard of care principle
advocated by Lurie and Wolfe.7 5
UNAIDS published its final version of its Guidance Document on Ethical
Considerations in HIV Preventive Vaccine Research in May 2000.76 Guid-
ance Principle 16 of this document addresses the standard of care issue at the
heart of the dispute of the placebo-controlled trials.77 UNAIDS concluded
that "[alt present, there is no universal consensus regarding the level of care
and treatment that should be provided."78 UNAIDS argued that its consul-
tations and deliberations produced three different ethical positions. Care and
70 Letter to Esparza, supra note 68. For a defense of the "highest attainable standard of care" princi-
ple, see Levine, supra note 35, at 533. Levine has played an important role in revising the Declaration of
Helsinki, CIOMS Guidelines, and the UNAIDS Guidance Document. See Public Citizen Press Release
Aug 1999, smpra note 68 (asserting that "[a]ll three of these documents have been written primarily by
Dr. Levine").
71 Letter to Esparza, supra note 68.
72 World Med. Ass'n, Declaration of Helsinki, as amended at the 52d WMA General Assembly,
Edinburgh, Scotland, Oct. 2000, http://www.wma.netlelpolicy/17-ce.html (visited Mar. 15, 2001)
[hereinafter Declaration of Helsinki (2000)].
73. Id. princ. 29.
74. Id. princ. 30.
75. Lurie and Wolfe noted how the World Medical Association had considered revising the Declara-
tion of Helsinki to allow for an ethical double standard but had ultimately rejected the double standard
for a universal standard based on the best proven level of care and treatment. See Letter from Peter Lurie
& Sidney M. Wolfe, Public Citizen, to Harold T. Shapiro, Chairman, National Bioethics Advisory Com-
mittee (Nov. 13, 2000), http://www.citizen.org/hrgfpublications/1545.hrm (visited Mar. 15, 2001)
[hereinafter Letter to Shapiro].
76 UNAIDS, ETHICAL CONSIDERATIONS IN HIV PREVENTIVE VACCINE RESEARCH, supra note 64.
77. Id at41.
78. Id.
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treatment for those who become infected should be provided (1) at the level
of care offered in the country sponsoring the vaccine research; (2) at the level
determined by the country hosting the vaccine research; or (3) at the level
that is consistent with the care available in the host country.79 Guidance
Principle 16 takes a procedural approach to setting the standard of care and
treatment. It sets the ideal standard as the "best proven therapy" and the
minimum standard of "the highest level of care attainable in the host coun-
try."80 Guidance Principle 16 then provides that a comprehensive care pack-
age should be agreed upon by consensus through a dialogue involving the
sponsor country, host country, and community representatives taking into
account a number of factors.81 UNAIDS' procedural approach to the stan-
dard of care clearly rejects the adoption of a universal standard to be applied
in all clinical trials wherever conducted.
The controversy Lurie and Wolfe started has provoked much sound and
fury within the scientific, medical, and public health communities. 82 As the
divergent paths taken by the World Medical Association and UNAIDS in
their respective positions on the ethical issue at the heart of the placebo-
controlled trials dispute reveal, consensus on the proper ethical approach has
not been reached. Lurie, Wolfe, and their allies continue to push the univer-
sal standard of care position in their evaluation of the work of ethical bodies
considering the issue. Lurie and Wolfe have criticized the ongoing work of
the U.S. government's National Bioethics Advisory Commission (NBAC) in
the preparation of a report on "Ethical and Policy Issues in International
Research." 83 They have argued that the NBAC is backing ethical standards
of care and treatment lower than those supported by the Declaration of Hel-
sinki (2000).84 In addition, Lurie, Wolfe, and five colleagues condemned the
NBAC's November 2000 revision of its September 2000 draft report to drop
the requirement of review of U.S. government-funded research in develop-
ing countries by a U.S. institutional review board.85 "The onus of partici-
79. Id. at 41-42.
80. I at 41.
81. Id. The factors are (1) level of care and treatment available in the sponsor country; (2) highest level
of care available in the host country; (3) highest level of treatment available in the host country;
(4) availability of infrastructure to provide care and treatment in the context of research; and (5) potential
duration and sustainabiliry of care and treatment for the trial participant. Id
82. Levine, supra note 35, at 532 (noting that the debate over the ethical justification for the placebo-
controlled trials triggered "the most acrimonious controversy over the ethics of clinical trials in recent
memory"); Lackey, supra note 19, at 4 (noting how Lurie and Wolfe's accusations "exploded like a bomb-
shell over the medical ethics community").
83. The most recent draft of the National Bioethics Advisory Commission's report on Ethical and
Policy Issues in International Research, dated September 29, 2000, can be found at http://bioethics.
gov/toc.html (visited Mar. 15, 2001).
84. Letter to Shapiro, supra note 75 (arguing that the NBAC draft report falls short of the Declaration
of Helsinki's ethical standards on what researchers are required to provide research subjects).
85. Letter from Peter Lurie, Deputy Director, Public Citizen's Health Research Group; George Annas,
Professor of Health Law, Boston University School of Public Health, Co-founder, Global Lawyers &
Physicians; Troyen A. Brennan, Chairperson, Human Subjects Committee, Harvard School of Public
Health; Arthur Caplan, Director, Center for Bioethics, University of Pennsylvania; Dirceu Greco, Profes-
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pant protection in such studies," the letter argued, "could be shifted from
the U.S. to the developing world, where the ethical review infrastructure...
is often grossly inadequate." 86 The resulting situation would not, of course,
support the adoption of a universal standard of care and treatment for clini-
cal research conducted in developing countries.87 Such an approach signals a
move towards an ethical double standard in connection with medical re-
search undertaken in developing countries by researchers from high-income
countries. The different approaches taken or considered by the World Medi-
cal Association, UNAIDS, CIOMS, and the NBAC suggest that the ethical
dispute triggered by Lurie and Wolfe continues to rage nationally and inter-
nationally.
III. THE PROBLEM OF GEOGRAPHICAL MORALITY IN INTERNATIONAL
RELATIONS THEORY
A. Edmund Burke and the Problem of Geographical Morality
The ethical conflict embodied in the placebo-controlled trials raises im-
portant questions within the larger context of international relations: How
do we morally and legally evaluate the behavior of the citizens of one coun-
try that takes place inside the territory of another country when the two
countries have different political, economic, cultural, religious, and histori-
cal heritages? How do we factor into this evaluation significant inequalities
in political and economic power and wealth between the two countries?
These questions are old ones in the study of international relations.
One of the earliest and most interesting attempts to come to grips with
these questions came from the eighteenth-century British statesman-
philosopher Edmund Burke in connection with his efforts to change British
imperial policy in India. In the course of his parliamentary career, Burke
became a fierce opponent of British imperial behavior in India, symbolized
most dramatically in his attempt to impeach Warren Hastings, governor-
general of Bengal, for high crimes and misdemeanors for the manner in
which Hastings ran the East India Company.88
sor, Internal Medicine, Coordinator of Infectious and Parasitic Disease Services, Chair, Federal University
of Minas Gerais Ethics Review Committee, Belo Horizonte, Brazil; Michael Grodin, Professor of Health
Law, Psychiatry, Socio-Medical Sciences and Community Medicine (Health and Human Rights), Boston
University Schools of Medicine and Public Health, and Sidney M. Wolfe, Director, Public Citizen's
Health Research Group, to Harold T. Shapiro, Chairman, National Bioethics Advisory Commission (Dec.
6, 2000), http://www.citizen.org/hrg/publications/1550.htm (visited Mar. 15, 2001) ("We are dismayed
and deeply disappointed that the National Bioethics Advisory Commission (NBAC) has seen fit to radi-
cally alter its draft report on the ethics of research in developing countries at the last minute to no longer
require review by a U.S. Institutional Review Board (IRB) of U.S. government-funded research in devel-
oping countries."),
86. Id
87. Id ("The result is a document that could actually lower ethical standards below those currently
accepted internationally.").
88 For analysis of the development of Burke's thinking on India, see David P. Fidler & Jennifer M.
Welsh, Introductuon to EMPIRE AND COMMUNITY: EDMUND BURKE'S WRITINGS AND SPEECHES ON IN-
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The development of the British empire in India confronted Burke and his
contemporaries with political, economic, legal, and moral questions gener-
ated by contact between a surging European great power and a weaker non-
European country. Burke argued that British imperial behavior in India had
degenerated into immoral and illegal exploitation of the Indian peoples.8 9
Burke believed that Hastings and the other employees of the East India
Company had engaged in arbitrary, despotic acts that destroyed indigenous
Indian politics, economics, and culture.90 Hastings argued in his defense
that he merely acted as oriental princes behaved in India and that he should
be judged according to the local standards of political behavior, not those
applicable in Great Britain.91 Burke rejected Hastings's defense,92 claiming
that Hastings was bound to run the East India Company on British princi-
ples and according to the "one, great, immutable, pre-existent law, prior to
all devices, and prior to all our contrivances, paramount to our very being
itself, by which we are knit and connected in the eternal frame of the uni-
verse, out of which we cannot stir."93 Burke argued that Hastings had for-
mulated:
a plan of Geographical morality, by which the duties of men in public
and in private situations are not to be governed by their relations to the
Great Governor of the Universe, or by their relations to men, but by
climates, degrees of longitude and latitude, parallels not of life but of
latitudes. As if, when you have crossed the equinoctial line all virtues
die.... and commence a new order and system of things.
TERNATIONAL RELATIONS 18-29 (D.P. Fidler & J.M. Welsh eds., 1999); F.G. WHELAN, EDMUND
BURKE AND INDIA: POLITICAL MORALITY AND EMPIRE (1996); CONOR CRUISE O'BRIEN, TH GREAT
MELODY: A THEMATIC BIOGRAPHY OF EDMUND BURKE 255-384 (1992). On the Hastings impeach-
ment, see THE IMPEACHMENT OF WARREN HASTINGS (G. Carnall & C. Nicholson eds., 1989).
89. Burke served on a parliamentary select committee that investigated between 1781 and 1783 the
abuses committed by the British East India Company in India. See Fidler & Welsh, npra note 88, at 22.
In the Ninth Report of the Select Committee, which Burke wrote, the Committee comprehensively analyzed
"the Principles of Policy, and the Course of Conduct, by which the Natives of all Ranks and Orders have
been reduced to their present State of Depression and Misery." Ninth Report of the Select Comnittee, in V
THE WRITINGS AND SPEECHES OF EDMUND BURKE 194, 197 (P.J. Marshall ed., 1981).
90. Speech on Fox's India Bill, in V THE WRITINGS AND SPEECHES OF EDMUND BURKE, .upra note 89,
at 378, 402 (arguing that "there is nothing before the eyes of the natives but an endless, hopeless pros-
pect of new flights of birds of prey and passage, with appetites continually renewing for a food that is
continually wasting").
91. Speech on Opening the Impeachment, in VI THE WRITINGS AND SPEECHES OF EDMUND BURKE 264,
348-49 (P.J. Marshall, ed., 1991) (quoting Hastings defending his actions by stating that "[t]he whole
history of Asia is nothing more than precedents to prove the invariable exercise of arbitrary power").
92. Id. at 349-50 ("You have heard his lecture upon arbitrary power .... Do your Lordships really
think that the nation would bear, that any human creature would bear, to hear an English Governor
defend himself upon such principles? ... Here he has declared his opinion that he is a despotic prince,
that he is to use arbitrary power, and of course all his acts are covered with that shield .... Will your
Lordships ever hear the corrupt practices of mankind made the principles of Government?").
93. Id. at 350.
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This Geographical morality we do protest against .... 94
Burke wanted to know exactly what the officers of the East India Company
were providing the natives of India:
What are the articles of commerce, or the branches of manufacture
which those gentlemen [of the East India Company] have carried hence
to enrich India? What are the sciences they beamed out to enlighten it?
What are the arts they introduced to chear and adorn it? What are the
religious, what the moral institutions they have taught among that
people as a guide to life, or as a consolation when life is to be no more
?95
To Burke, Hastings's arguments were little more than a poor excuse for
British exploitation of India. Hastings's position also involved notions of
British and European superiority over Indian civilization, which represented
a cultural chauvinism that Burke rejected. 96 Burke realized that Hastings's
"plan of Geographical morality" would appeal to members of parliament,
and he chastised them for not giving proper attention and concern to the
poor, unfortunate inhabitants of India who were victims of British exploita-
tion perpetuated through behavior based on a double standard. 97 "[T]he
cries of India," argued Burke, "are given to seas and winds, to be blown
about, in every breaking up of the monsoon, over a remote and unhearing
ocean." 98
The Burke-Hastings conflict is important because in it we see the basic
features of the ethical controversy surrounding the placebo-controlled trials.
Critics of these trials argue that the "local standard of care" defense of the
trials is unethical and disguises the exploitation of poor countries by pow-
erful countries. 99 Allowing local public health and health care conditions to
affect the ethical analysis means that moral judgments are driven by geo-
graphical parameters. In other words, the placebo-controlled trials revealed a
contemporary "plan of Geographical morality" at work in the world of in-
ternational clinical trials.
94 Id. at 346.
95. Speech on Nabob of Arcot's Debts, in V THE WRITINGS AND SPEECHES OF EDMUND BURKE, supra
note 89, at 478, 494.
96. Speech on Opening the Impeachment, supra note 91, at 361 ("I assert that their [the Indians'] morality
is equal to ours as regards the morality of Governors, fathers, superiors; and I challenge the world to
shew, in any modern European book, more true morality and wisdom than is to be found in the writings
of Asiatic men in high trusts, and who have been Counsellors to Princes."); Speech on Fox's India Bill, supra
note 90, at 389 ("This multitude of men [the Indians] does not consist of an abject and barbarous popu-
lace; much less gangs of savages ... ; but a people for ages civilized and cultivated; cultivated by all the
arts of pohished life, whilst we were yet in the woods.").
97. Speech on Fox's India Bill, supra note 90, at 381 (Burke attacking his fellow members of parliament
for "the total silence of these gentlemen concerning the interest and well-being of the people of India").
98. Id. at 403.
99. Lurie & Wolfe, supra note 15, at 855; Annas & Grodin, supra note 25, at 561; Brennan, supra note
25, at 529-30; Public Citizen Press Release Aug. 1999, supra note 68.
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This analogy is not intended to suggest that the U.S. National Institutes
of Health, U.S. Centers for Disease Control and Prevention, and the re-
searchers they sponsored acted in arbitrary and despotic ways like the officers
of the East India Company. Instead, it highlights the basic features of the
placebo-controlled trials controversy, the complexities of which will be ex-
amined below. In addition, the "plan of Geographical morality" Burke criti-
cized represents in microcosm a larger controversy in international relations
theory about the role of ethics and international law in international politics.
This larger controversy is also important in examining the ethical debate
over the placebo-controlled trials.
B. Ethics, International Law, and International Relations
The role of ethics and international law in international relations has been
the subject of much debate in international relations theory. A simple, but
still helpful, approach to this controversy is to look at the importance given
to ethics and international law in Martin Wight's three traditions of interna-
tional theory: realism, rationalism, and revolutionism.100
1. Realism
Realism holds that morality has no place in the relations among states. 0 1
If ethics has a role in human life, that role is at the personal level rather than
the political level. 10 2 The anarchical nature and dynamics of the interna-
tional system force moral considerations to retreat to the private realm,
where they become unimportant for explaining the behavior of states in the
international system.
If states use the language of ethics in their relations with other states,
such language is merely a diplomatic ploy that no statesperson takes seri-
ously.10 3 Thucydides famously captured this attitude in the Melian Dialogue
when the Athenian envoys, who are denied access to speak to the people of
Melos, encourage the Melian leaders to drop all pretenses of justice and mo-
rality in their discussions with the Athenians. 10 4 E.H. Carr, a twentieth-
100. MARTIN WIGHT, INTERNATIONAL THEORY: THE THREE TRADITIONS (G. Wight & B. Porter
eds., 1991).
101. See THUCYDIDES, HISTORY OF THE PELOPONNESIAN WAR 331 (R. Crawley trans., 1951) (re-
counting the famous Melian Dialogue, where the Athenians argue to the Melians that "you know as well
as we do that right, as the world goes, is only in question between equals in power, while the strong do
what they can and the weak suffer what they must."); EDWARD HALLETT CARR, THE TWENTY YEARS'
CRISIS, 1919-1939, at 64 (2d ed. 1946) (citing Machiavelli's realist belief that "[mjorality is the product
of power"); HANS J. MORGENTHAU, POLITICS AMONG NATIONS 10-11 (5th ed. 1978) (arguing that
there are no universally agreed principles of moral behavior that guide state actions).
102. WIGHT, supra note 100, at 245 (arguing that in realism "[t]he validity of ethics is restricted to
private relations, and politics is left as the domain of the non-ethical').
103. See, ag., MORGENTHAU, Supra note 101, at 11 ("All nations are tempted-and few have been able
to resist the temptation for long-to clothe their own particular aspirations and action in the moral
purposes of the universe.").
104. THUCYDIDES, supra note 101, at 330-37.
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century realist, similarly argued that moral reasoning in international rela-
tions was merely a way to justify power-political behavior.10 5 The accumula-
tion, maintenance, and exercise of power are what the statesperson seeks.
10 6
As the twentieth-century realist Hans Morgenthau argued, "statesmen think
and act in terms of interest defined as power."' 0 7 Similarly, international law
is merely another tool in the game of power politics. 10 8 As Jean-Jacques
Rousseau grimly put it, "justice and truth must be bent to serve the most
powerful; that is the rule."'1 9 Whether individuals rely on ethical principles
in conducting transnational activities is of no concern to the realist, whose
analytical focus remains fixed on the state and its behavior in the game of
power.
2. Rationalism
Rationalism holds that states can find ways to structure their relations to
avoid simply engaging in a perpetual and violent power struggle. 110 Ration-
alists do not deny that the anarchical nature of inter-state relations creates a
difficult milieu for co-existence and cooperation, but they believe that states
can agree on certain common interests and values that support more orderly
and peaceful international relations."' This position creates more potential
for ethical considerations and international law to play a role in international
politics.'12
105 CARR, supra note 101, at 79-80 ("Theories of international morality are ... the product of
dominant nations or groups of nations .... For the past hundred years.... the English-speaking peoples
have formed the dominant group in the world; and current theories of international morality have been
designed to perpetuate their supremacy ... ").
106. Timothy Dunne, Realism, in THE GLOBALIZATION OF WORLD POLITICS 109, 115 (J. Baylis & S.
Smith eds., 1997) (noting the realist principle of accumulation of power).
107. MORGENTHAU, SUpra note 101, at 5.
108. Scott Burchill, Realism and Neo-Realism, in THEORIES OF INTERNATIONAL RELATIONS 67, 80 (S.
Burchill et al. eds., 1996) (noting that in realism "[i]nternational law was regarded sceptically, particu-
larly if states believed that it infringed on their capacity to pursue their national interests"); WIGHT,
supra note 100, at 235 (arguing that under realism "international law operates in the domain of subsidi-
ary importance").
109. Jean-Jacques Rousseau, The State of War, in ROUSSEAU ON INTERNATIONAL RELATIONS 33, 43
(S. Hoffmann & D.P. Fidler eds., 1991).
110 WIGHT, supra note 100, at 13 (arguing that rationalists "are those who concentrate on, and be-
lieve in the value of, the element of international intercourse in a condition predominantly of interna-
tional anarchy"); Andrew Linklater, Rationalism, in THEORIES OF INTERNATIONAL RELATIONS, supra note
108 at 93, 94 (arguing that "rationalism begins with anarchy but unlike realism it acknowledges that the
sense of belonging to the community of humankind has left its civilizing mark upon the state and inter-
national relations").
111. WIGHT, supra note 100, at 39 (characterizing rationalism as believing in the existence of an in-
ternational society that involves the use of international law); Linklater, supra note 110, at 100 (arguing
that "rationalism considers the processes by which systems of states are transformed into international
societies and focuses upon the normative and institutional expressions of society between states").
112. See WIGHT, supra note 100, at 238, 241-44 (discussing rationalist perspectives on international
legal obligations and international ethics); Robert H. Jackson, The Political Theory of International Society,
in INTERNATIONAL RELATIONS THEORY TODAY 110, 114 (Ken Booth & Steve Smith eds., 1995) (noting
the importance of international law to rationalism); Linklater, supra note 110, at 100-04 (noting the
importance of questions of justice and morality to rationalism).
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In connection with ethics, rationalism exhibits two different strands of
thought: pluralism and solidarism. 113 Pluralism acknowledges that states
have different domestic political, economic, and cultural systems but holds
that even diverse states can, at the international level, form a society with
moral and legal rules.114 The morality is, however, a morality of states, not of
domestic political systems or individuals. 115 The diversity within states
makes it difficult, if not impossible, to project moral principles applicable
domestically to governments and individuals onto states and their political
and economic interactions. The basis of inter-state morality is the practices
of states in their systemic interactions rather than a priori principles or natu-
ral law.116 Similarly, the rules of international law in a pluralistic vision of
international society flow from the patterns of state behavior, not from ab-
stract moral principles. This rationalistic idea can be seen in Article 38(1) of
the Statute of the International Court of Justice, which lists the major
sources of international law, all of which derive from actual state practice
and state consent, and not natural law thinking. 1 7
Solidarism holds that the society of states rests upon a foundation of po-
litical, economic, and social like-mindedness within states.118 International
society and international law are weak under pluralism, and only similitude
domestically among states provides a strong foundation for a role for moral-
ity and international law in international relations. 119 Domestic political,
economic, and cultural homogeneity means that states share important val-
ues, principles, and interests and will be able to use this homogeneity as a
basis for more effective cooperation. Solidarism creates the conditions neces-
113. Fidler & Welsh, supra note 88, at 52 (noting that in the international society tradition of interna-
tional relations thinking, pluralist and solidarist approaches can be discerned); Linklater, supra note 110,
at 100 (noting how rationalism distinguishes between pluralistic and solidaristic international societies).
114. Fidler & Welsh, supra note 88, at 52. For more on pluralism, see Andrew Hurrell, Vattel: Plural-
ism and Its Limits, in CLASSICAL THEORIES OF INTERNATIONAL RELATIONS 233 (Ian Clark & Iver B.
Neumann eds., 1996).
115. Fidler & Welsh, supra note 88, at 52; Linklater, supra note 110, at 100 (noting that "[a]ccording
to the pluralist perspective .... the members of that [international] society are states rather than indi-
viduals").
116. WIGHT, supra note 100, at 39 (noting that rationalists see international society as a customary
society-a society built out of the shared customs and practices of states).
117. See Statute of the International Court ofJustice, June 26, 1945, art. 38(1), 59 Stat. 1055.
118. Fidler & Welsh, supra note 88, at 52-53 (discussing the solidaristic perspective).
119. Edmund Burke expressed this idea when he wrote that
[w]e lay too much weight upon the formality of treaties and compacts .... Men are not tied to one
another by papers and seals. They are led to associate by resemblances, by conformities, by sympa-
thies. It is with nations as with individuals. Nothing is so strong a tie of amity between nation and
nation as correspondence in laws, customs, manners, and habits of life. They have more than the
force of treaties in themselves. They are obligations written in the heart.
First Letter on a Regicide Peace, in IX THE WRITINGS AND SPEECHES OF EDMUND BURKE 187, 247 (R.B.
McDowell ed., 1991). For more on Burke's solidaristic approach to international relations, see Jennifer
M. Welsh, Edmund Burke and the Commonwealth of Europe: The Cultural Bases of International Order, in CLAS-
sIcAL THEORIES OF INTERNATIONAL RELATIONS, supra note 114, at 173.
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sary to facilitate an important international role for ethical and international
legal principles for both states and individuals. 120
While solidarism offers a stronger foundation for ethics and international
law than pluralism, rationalism's goal is, at best, the approximation of moral
standards rather than their complete fulfillment.12' The anarchical environ-
ment of international politics makes more than the approximation of ethical
principles difficult, even in the case of like-minded states. In addition, plu-
ralism and solidarism can simultaneously exist in the international system as
some states will exhibit homogeneity while others do not. Ethical conun-
drums arise when states and individuals from the solidaristic core engage
with states and peoples outside the core. 122 Even in situations where the
ethical and legal principles of the core are applied to or accepted by the pe-
riphery, socio-economic problems in the periphery complicate full applica-
tion of the core's principles. This problem is at the heart of the controversy
over the placebo-controlled trials because the poor economic and health con-
ditions in developing countries complicate the application of ethical stan-
dards primarily established by and used in developed countries.
3. Revolutionism
One of the characteristic features of revolutionism as a theory of interna-
tional relations is the belief in the moral unity of humanity.123 It is, thus, the
opposite of realism's amorality.124 The limited state morality of pluralistic
rationalism underemphasizes, in revolutionism's view, the underlying moral
unity of humankind. 25 Pluralistic international law embodies principles of
behavior that reinforce divisions in humanity rather than build unity across
borders. 126 Revolutionism is closest in outlook to solidaristic rationalism,
120 Hedley Bull, The Grotian Conception of International Society, in DIPLOMATIc INVESTIGATIONS: ES-
SAYS IN THE THEORY OF INTERNATIONAL POLITIcS 52, 64 (Herbert Butterfield & Martin Wight eds.,
1966) (arguing that solidarity in international society involves not only states but also assumes "that
individual human beings are subjects of international law and members of international society in their
own right").
121 WIGHT, supra note 100, at 243 ("Ideals are never realized, but should be striven for; the funda-
mentals wherein we believe will not be carried out, but it is necessary to affirm them: here is the moral
tension within which Rationalist statecraft is conducted."); Linklater, supra note 110, at 101 (stressing
how rationalism represents a middle way between the pessimism of realism and the optimism of cos-
mopolitanism).
122. Fidler & Welsh, stpra note 88, at 53 (discussing how solidarism raises questions about inter-
course between different cultures).
123. WIGHT, supra note 100, at 40-41 (arguing that a characteristic of revolutionism is its conception
of the world as a single society, a civitas maxima).
124 Id at 40 (noting how revolutionism differs from realism in its conception of a unified humanity);
Jackson, supra note 112, at 114 (noting that "fr]evolutionism assumes a world society in which states,
while present, nevertheless are subject to certain moral obligations to human beings, who in some fun-
damental respects are prior to them").
125 WIGHT, supra note 100, at 40 (noting how revolutionism differs from rationalism in its concep-
tion of a unified humanity); Jackson, supra note 112, at 114 (contrasting rationalism's concern with or-
derly intercourse between states and revolutionism's concern with the unity of humankind).
126. This sentiment is apparent in Immanuel Kant's description of Grotius, Puffendorf, and Vattel as
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but revolutionism is more radical because it postulates a universal moral
unity without the cultural and socio-economic boundaries implicit in solida-
ristic rationalism.
Revolutionism advocates that political action has to be directed toward
the achievement of political, economic, and cultural moral unity of human-
ity.'27 This moral unity, in short, becomes the lodestar for national, transna-
tional, and international action. Revolutionism frowns upon compromising
moral objectives in the face of difficult political and economic conditions.
Different strands of revolutionism take divergent positions on international
law. Revolutionism d la Kantian liberalism attempts to harness international
law by transforming it into a progressive tool for building perpetual
peace. 128 Revolutionism a la Marxism has no progressive role for interna-
tional law because such law represents the very system that has to be de-
stroyed to achieve human unity.129
4. The Three Traditions, the Geographical Morality Problem, and the Placebo-
Controlled Trials
Realism, rationalism, and revolutionism take different positions in con-
nection with the problem of "geographical morality." Revolutionism is hos-
tile toward notions of geographical morality in ethics or international law
because of its fundamental attachment to the moral unity of humanity. Any
plan of geographical morality is an attack on this moral unity and must be
opposed.
Pluralistic rationalism opens space for the concept of geographical moral-
ity because it recognizes that states often have different political, economic,
and cultural systems that are not assimilated in any common ideology or
shared moral code. In a pluralistic framework, international law reflects the
diversity of states by not requiring governments and individuals to follow
rules based on one particular ethical system. Morality is, by definition, geo-
graphical under pluralistic rationalism.
Solidaristic pluralism reduces the space for geographical morality because
states within the solidaristic core share ethical codes nationally and interna-
tionally. Under solidarism, the common ethical principles of the core
influence the substance of international law as the states in the solidaristic
"miserable comforters all of them" because their arguments "are still always quoted cordially for the
justification of an outbreak of war." IMMANUEL KANT, ETERNAL PEACE AND OTHER INTERNATIONAL
ESSAYS 82-83 (W. Hastie trans., 1914).
127. WIGHT, supra note 100, at 41-48 (discussing strands of revolutionism that seek to unify hu-
mankind in different ways).
128. See KANT, supra note 126, at 81--86 (explaining the second definitive article of the conditions for
perpetual peace, which involves the transformation of the law of nations). For more on Kant's interna-
tional thinking, see Howard Williams & Ken Booth, Kant: Theorist Beyond Limits, in CLASSICAL THEO-
RIES OF INTERNATIONAL RELATIONS, supra note 114, at 71.
129. See V. KUBALKOVA & A.A. CRUICKSHANK, MARXISM AND INTERNATIONAL RELATIONS 17-18
(1985) (listing the essential features of the Marxist tradition, including the proposition that "[t]he sub-
stance of international relations ... is inter-class relations").
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core translate shared moral understandings into binding international legal
commitments. The problem of geographical morality largely disappears in
the moral and legal homogeneity characterizing state relations in the core.
Geographical morality remains a problem for solidaristic rationalism in con-
nection with relations between the states in the solidaristic core and states
not integrated into the political, economic, and cultural heritage shared by
states in the core.
The ethical controversy over the placebo-controlled trials looks like a de-
bate between a perspective that echoes revolutionism and one that is sugges-
tive of solidaristic rationalism. Those critical of the placebo-controlled trials
apply a universal ethical framework that insists that a research subject in a
clinical trial in a developing country receive exactly the same treatment as
one in a developed country.130 Explicit in this universalist position is the
belief in the moral unity of humankind and that this unity should guide
action related to the conduct of clinical trials. In other words, human rights
are universal; and compromising a poor person's rights for scientific utility
or reasons related to the different socio-economic context of poor countries is
ethically illegitimate.
Defenders of the placebo-controlled trials sound like solidaristic rational-
ists influenced by liberalism. First, the defenders believe in a shared ethical
code for conducting clinical trials; the defenders of the placebo-controlled
trials have not rejected international ethical codes such as the Nuremberg
Code and the Declaration of Helsinki but are interpreting these ethical prin-
ciples differently from the opponents of the trials. The ethical framework in
the Nuremberg Code and the Declaration of Helsinki comes out of liberal
political thinking because respect for individual rights is central to the en-
tire framework. 131 Liberalism is the philosophical foundation of solidaristic
rationalism in contemporary international relations because liberalism has
become the dominant political philosophy in world affairs.
132
Second, the defenders of the placebo-controlled trials are willing to com-
promise on the application of the framework in socio-economic contexts
radically different from those in the states in the solidaristic core. Echoing
rationalism, the defenders of the placebo-controlled trials seek to approxi-
mate ethical objectives in activities outside the core rather than dogmati-
cally insisting on the complete fulfillment of every ethical rule applied
130. See Annas & Grodin, supra note 25, at 561 (arguing that human rights are universal and that ap-
peals by Varmus and Satcher to the support of local African researchers for the placebo-controlled trials
implies support for an outdated and dangerous view of cultural relativism").
131. David R Fidler, Caught Between Traditions: The Security Council in Philosophical Conundrum, 17
MICH. J. INT'L L. 411, 413 (1996) ("Liberalism refers to a body of thought the core of which is the lib-
erty of the individual .... Liberalism posits ... that international relations is not fundamentally about
obtaining power as a shield against anarchy but is about protecting individual liberty at home while
fostering individual liberty overseas.").
132. See, e.g., Francis Fukuyama, The End of History?, THE NATIONAL INTEREST, Summer 1989, at 3
("The triumph of the West, of the Western idea, is evident... in the total exhaustion of viable systematic
alternatives to Western liberalism.").
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within the core. 133 Geographical morality is not an abandonment of ethics
but a practical application of an ethical code in socio-economic conditions
alien to the states of the solidaristic core.
While revolutionism and rationalism are relevant perspectives on moral-
ity in connection with the placebo-controlled trials controversy, realism ap-
pears at first glance unhelpful. A realist would argue, however, that realism's
perspective on morality in international relations remains relevant. Realism
sees in both defenders and critics of the placebo-controlled trials different
excuses for exploitation of the weak by the strong. Defenders of the placebo-
controlled trials have difficulty countering the accusation that the therapy
tested in the placebo-controlled trials would not have been affordable to
people in developing countries. 134 It is most likely that the trials will only
provide benefits to developed countries; geographical morality presented as
practical ethics in international relations therefore merely disguises an ex-
ploitative undertaking. 135 Realists would not be squeamish about engaging
in exploitation through clinical trials if such trials produced results that
augment the power of the state sponsoring the research by providing it with
cheaper HIV drugs.
Critics of the placebo-controlled trials also face a realist charge of exploi-
tation in one of two forms. First, comparing the 076 regimen against a
shorter course of AZT would also be exploitation because neither the 076
regimen nor the AZT short course would be affordable in developing coun-
tries. 136 Second, refusing for ethical reasons to conduct either 076 regi-
men/short course AZT equivalency trials or placebo-controlled trials merely
represents the exercise of scientific and technological power by rich states
over weak states. The ethical discourse merely masks unconvincingly the
true nature of the power politics taking place. The North's "ethical con-
science" pretends to purity while people in the South continue to die from
HIV/AIDS with no therapeutic drugs in sight to relieve individual suffering
and societal devastation. Again, realists are unmoved by this suffering and
133. See, e.g., Bayer, supra note 35, at 570 (arguing that the dispute over the placebo-controlled trials
is about how to apply agreed-upon principles to different social conditions); David B. Resnik, The Ethics
of HIV Research in Developing Nations, 12 BioEics 286 (1998) (arguing that standards of ethical re-
search are universal but not absolute because the application of the standards must take into account
factors inherent in particular situations); Robert Baker, A Theory ofInternational Bioethics: The Negotiable
and Non-Negotiable, 8 KENNEDY INST. OF ETHics J. 233 (1998) (arguing that moral universalism col-
lapses under multicultural and postmodernist critiques and that international ethical research standards
can be grounded in a rationally negotiated moral order).
134. See, e.g., Annas & Grodin, supra note 25, at 561 (arguing that "In]either NIH nor CDC (nor the
host countries) has a plan that would make the interventions they are studying available in Africa, where
more than two thirds of the people in the world reside who are infected with HIV").
135. Id. ("Unless the interventions being tested will actually be made available to the impoverished
populations that are being used as research subjects, developed countries are simply exploiting them in
order to quickly use the knowledge gained from the clinical trials for the developed countries' own
benefit.").
136. Levine, supra note 35, at 533 (arguing that "Mor several reasons, most of which are economic,
the 076 regimen cannot be made available to residents of developing countries on a continuing basis").
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devastation unless it factors into the power calculus of international rela-
tions. If the North discontinues such placebo-controlled trials, then the rea-
son has to do with national interests of powerful states rather than universal
ethical principles.
In sum, four distinct perspectives on the problem of geographical moral-
ity can be identified in international relations theory:
Cynical. For realism, there is no tactical or strategic difference between
basing policy on universalism or a plan of geographical morality. Both are
merely expedient justifications for states thinking and acting in terms of
interest defined as power.
Hostile. Revolutionism is hostile toward any plan of geographical moral-
ity because universalism is at the heart of the revolutionist tradition.
Complacent. Pluralistic rationalism can be interpreted as being complacent
about geographical morality because international morality (i.e., morality
between states) and international law in this tradition do not concern them-
selves directly with this problem. Indeed, under pluralistic rationalism, no
shared system of ethical and legal behavior unites all peoples and govern-
ments. While pluralism encourages the development of interstate morality,
it does not seek to harmonize ethical and legal principles inside states.
Concerned. Solidaristic rationalism can be interpreted as exhibiting con-
cern about the problem of geographical morality, but the concern neither
rises to the level of hostility nor sinks to the depths of cynicism. Outside the
solidaristic core, radically different socio-economic conditions affect how the
ethical and legal principles shared by the core operate. As a pragmatic mat-
ter, "double standards" have to be tolerated to a certain degree. Such ethical
pragmatism makes solidarists uneasy, and the long-term objective is to cre-
ate the conditions that would allow the solidaristic core to expand and in-
clude areas now in the periphery.
IV. THE PROBLEM OF GEOGRAPHICAL MORALITY IN INTERNATIONAL LAW
The geographical morality problem also affects international law. The area
in which this problem has most prominently appeared is in international
human rights law. As shown by the analysis in Part III, only liberal solida-
ristic rationalism and liberal revolutionism support a vigorous concept of
human rights in international law. Realism has little tolerance for the con-
cept of human rights;137 and pluralistic rationalism could only, at best, sup-
port a minimalist international law on human rights.138 As Vincent argued,
"because of their suspicion of each other, and their worries about the causes
and effects of intervention, the members of international society are united
137 R.J. VINCENT, HUMAN RIGHTS AND INTERNATIONAL RELATIONS 121 (1986) (noting that, un-
der realism, "'the ascendancy of this or that theory of rights is merely the manifestation in doctrine of an
underlying political balance").
138, Id at 113-18 (discussing the impact of pluralism on concepts of human rights).
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by a principle of non-intervention which bears witness to their minimal
solidarity: not the absence of morality but the recognition of its limits."'139
The geographical morality problem has also been manifest in interna-
tional human rights law in the long-running debate between universalists
and cultural relativists. Universalists hold that human rights embodied in
international law universally apply to every human being no matter where
he or she lives.140 Cultural relativists deny the universality of human rights
and claim that much of international human rights law derives from a
specific cultural and philosophical source. 141
The controversy over the placebo-controlled trials does not, however, in-
volve a clash between universalism and cultural relativism. Both critics and
defenders of the placebo-controlled trials believe in the universality of hu-
man rights. The critics of the placebo-controlled trials argue that the de-
fenders of such research have violated human rights, yet refrain from accusa-
tions that the defenders do not believe in human rights. One can see in the
defenders of the placebo-controlled trials a procedural and contextual ap-
proach to the universal application of human rights. The geographical mo-
rality problem in these circumstances is, thus, more complex than univer-
salism v. cultural relativism.142 This complexity includes not only the rele-
vance of solidaristic rationalism but also the actual content of international
human rights law and its application to the placebo-controlled trials. This
Part IV delves into the international human rights law implicated by the
placebo-controlled trials.
A. The Relevance of International Law
International law on human rights recognizes two basic kinds of funda-
mental human rights: (1) civil and political rights; 14 3 and (2) economic, so-
cial, and cultural rights.144 Civil and political rights include the right to
139. Id. at 114.
140. See, e.g., Vienna Declaration and Programme of Action, World Conference on Human Rights, at 1,
UN Doc. A/CONF.157/23 (1993):
The World Conference on Human Rights reaffirms the solemn commitment of all States to fulfil
their obligations to promote universal respect for, and observance and protection of, all human
rights and fundamental freedoms for all in accordance with the Charter of the United Nations, other
instruments relating to human rights, and international law. The universal nature of these rights
and freedoms is beyond question.
141. VINCENT, supra note 137, at 37-38 (arguing that cultural relativism asserts that there is no uni-
versal morality and that the attempt to assert such a morality is imperialistic).
142. See Bayer, supra note 35, at 570:
[Tihis debate is not an instance of the ongoing clash between those ... who believe that a single
Western-dominated ethical standard should apply to all research and others who believe that ethical
standards should reflect local values. Rather than a clash over first principles, this is a dispute over
the application of agreed-upon principles in radically different social conditions.
143. See International Covenant on Civil and Political Rights, openedfor signature Dec. 16, 1966,-
U.S.T.-, 999 U.N.T.S. 171 [hereinafter ICCPR].
144. See International Covenant on Economic, Social, and Cultural Rights, openedfor signature Dec. 16,
1966, 993 U.N.T.S. 3, 6 I.L.M. 383 [hereinafter ICESCR). This analysis focuses on the so-called "first"
and "second" generations of human rights but does not address the more controversial "third" and
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life;145 the right not to be subject to torture or cruel, inhuman, or degrading
treatment or punishment; 146 the right to liberty and security of person;
147
the right to liberty of movement; 148 the right to a fair trial;149 and the right
to freedom of expression. 150 States must protect civil and political rights
without discriminating on any grounds. 151
Economic, social, and cultural rights include the right to work; 152 the
right to form and join trade unions; 153 the right to social security;154 the
right to an adequate standard of living;155 the right to health;156 and the
right to enjoy the benefit of scientific progress. 157 States must not discrimi-
nate on any grounds in ensuring individuals their economic, social, and cul-
tural rights. 158
This discussion of international law on human rights may strike the
reader as odd given that the debate over the placebo-controlled trials has
been conducted at the ethical rather than the legal level. What is the rele-
vance of international law on human rights? First, one might argue that
some of the rules in the ethical framework for research involving clinical
trials have international legal status through treaty law or customary inter-
national law. For example, George Annas has argued that the Nuremberg
Code is an international legal document. 159 In addition, a fundamental rule
of the Nuremberg Code-the right not to be subjected to medical or sci-
entific experimentation without free consent-has appeared in human rights
treaties, such as the International Covenant on Civil and Political Rights(ICCPR).160
"fourth" generations of human rights that consist of group rights as opposed to strictly individual rights.
These group rights are excluded from the analysis because the ethical debate over the placebo-controlled
trials has focused on the rights of individuals as opposed to peoples. This article's focus on the first two
generations of human rights does not mean that analysis of the placebo-controlled trials from the per-
spective of group rights would be irrelevant or unhelpful.
145 See ICCPR, supra note 143, art. 6(1).
146. See id. art. 7.
147, Seetd. art, 9(1).
148, Seeid. art. 12(1).
149 Seeid. art. 14.
150. See id. art. 19(2).
151, Seeid. art. 2(1).
152. See ICESCR, supra note 144, art. 6(1).
153, See Id. art. 8(l).
154. See Id. art. 9.
155. See Id art. 11(1).
156. See Id. art. 12(1).
157 See Id. art. 15(1X).
158. See Id art. 2(2).
159. George J. Annas, The Changing Landscape of Human Experimentation: Nuremberg, Helsinki, and Be-
yond, 2 HEALTH MATRIX 119, 121 (1992) (claiming that the Nuremberg Code is "the most authoritative
legal and ethical document governing international research standards, and one of the premier human
rights documents in world history").
160 ICCPR, supra note 143, art. 7. For analysis of ICCPR Article 7, see Todres, supra note 26, at
743-46. Part IV.C.2 infra discusses the relevance of the principle of free consent to the placebo-controlled
trials,
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Second, one might argue that the principles of the Nuremberg Code,
Declaration of Helsinki, and CIOMS Guidelines have become customary
international law binding on all states except persistent objectors. 161 To be-
come a rule of customary international law, a principle must be supported by
(1) general and consistent state practice; and (2) evidence that the general
and consistent state practice is followed out of a sense of legal obligation,
called opinio juris.162 Rules of customary international law are binding on all
states except those that persistently object to the rule in question.163 Exami-
nation of the behavior of government funding of national and international
clinical trials might reveal some general and consistent state practice sup-
porting the basic principles of the Nuremberg Code, Declaration of Helsinki
and CIOMS Guidelines.'64 As the Nuffield Council on Bioethics indicated,
the Declaration of Helsinki and CIOMS Guidelines "have no inherent legal
authority but are referred to by many regulatory bodies involved in formu-
lating ethical guidelines or regulations for biomedical research."'165 Such an
examination might also reveal evidence that the general and consistent state
practice is supported by opiniojuris.166
Third, general principles of law recognized by civilized nations-a third
primary source of international law167 -might support the incorporation of
international ethical standards into international law because many national
systems of law require satisfaction of ethical standards in connection with
government-funded research. 168 The ethical standards as embodied in do-
mestic law may be seen as general principles of law that can be elevated to
binding international law if their widespread adoption throughout the in-
ternational system is shown.
Fourth, both international human rights law and ethical codes function to
protect individuals, indicating that human rights law and the ethical codes
161. The most recent amendment of the Declaration of Helsinki (2000) complicates arguments that
the principles in the Declaration represent customary international law. The debates over the ethics of the
placebo-controlled trials used the Declaration of Helsinki (1996), supra note 31, not the Declaration of
Helsinki (2000), supra note 72, as the point of reference. For this reason, this Article primarily uses the
Declaration of Helsinki (1996) in the international legal analysis because the Declaration of Helsinki
(2000) has not been in existence long enough to influence state practice significantly for purposes of
customary international law analysis.
162. IAN BROWNUE, PRINCIPLES OF PUBLIC INTERNATIONAL LAw 5-8 (5th ed. 1998).
163. id. at 10.
164. See, e.g., Protection of Human Subjects, 45 C.F.R. § 46 (1994).
165. NUFFIELD COUNCIL ON Bxoaics, THE ETHics OF CLINICAL RESEARCH IN DEVELOPING
CouNTRF.s 6 (1999).
166. The author is not aware that such an examination has ever been undertaken for purposes of de-
termining whether customary international law exists in this area. Such an examination would confront
problems inherent in the methodology of locating a rule of customary international law. Evidence of
opinio juris is, for example, hard to locate and interpret. See David P. Fidler, Challenging the Classical Con-
cept of Custom: Perspectives on the Future of Customary International Law, 39 GE.MN YB. INT'L L. 198, 204-
08 (1996) (discussing problems inherent in the concept of opinio juris); J. Patrick Kelly, The Twilight of
Customary International Law, 40 VA. J. INT'L L. 449, 469-75 (2000) (analyzing the methodological prob-
lem of determining opiniojuis).
167. See ICJ Statute, supra note 117, art. 38(1Xc).
168. See, e.g., Protection of Human Subjects, supra note 164.
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flow from a common value system that elevates the importance of the indi-
vidual.1 69 Even if the ethical codes do not have international legal status,
their close relation to international human rights law justifies an interna-
tional legal analysis of the placebo-controlled trials.
B. Is the Ethical Standard of "Best Proven Diagnostic and Therapeutic Method"
Part of International Law?
The first question is whether the ethical standard of providing every clini-
cal trial patient with the "best proven diagnostic and therapeutic method,"
as required by the Declaration of Helsinki,170 forms part of international
law. No treaty embodies this principle. Whether this standard can be con-
sidered international law through customary international law or general
principles of law is debatable. The controversy over placebo-controlled trials
suggests that disagreement exists among different countries and experts
about what this ethical standard means and requires from governments and
researchers involved in clinical trials. 171 As Salim Abdool Karim argues:
The reality is that standards-in this case, the standard of care--differ
across the world and even within countries; they are seldom agreed
upon internationally. Although the ACTG 076 regimen of therapy is
the standard of care in some countries, it is not an international stan-
dard, such as is set by the World Health Organization.17 2
As noted earlier, UNAIDS concluded in May 2000 that no consensus exists
internationally to support a universal standard of care and treatment. l7 3
These observations make the substance of the "best available standard of
care" ambiguous at best. Even if one were to claim that "the best available
standard of care" is a principle of customary international law binding on
states, the ambiguity in the standard means that the placebo-controlled tri-
als would not necessarily be in violation of international law.
Nor do the October 2000 amendments to the Declaration of Helsinki, the
May 2000 publication of the UNAIDS Guidance Document, or the pro-
posed revisions to the CIOMS Guidelines necessarily clarify the substance of
any international legal standard requiring the best proven diagnostic and
169. See Declaration of Helsinki (2000), supra note 72, princ. 8 ("Medical research is subject to ethical
standards that promote respect for all human beings and protect their health and rights.").
170. Declaration of Helsinki (1996), supra note 31, at 11.3; Declaration of Helsinki (2000), supra note
72, princs. 29, 30 (ethical standard of providing "the best proven prophylactic, diagnostic or therapeutic
method").
171 This disagreement points to divergent state practice and opinio juris, undermining arguments
that the "best proven diagnostic and therapeutic method" standard as interpreted by opponents of the
placebo-controlled trials is a rule of customary international law.
172. Salim S. Abdool Karim, Placebo Controls in HIV Perinatal Transmission Trials: A South African's
Viewpoint, 88 AM.J. PuB. HEALTH 564, 565 (1998).
173. UNAIDS, ETHICAL CONSIDERATIONS IN HIV PREVENTIVE VACCINE RESEARCH, supra note 64,
at 41
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therapeutic method. The World Medical Association (WMA) controls the
Declaration of Helsinki, and CIOMS administers the CIOMS Guidelines;
the WMA and CIOMS are non-governmental organizations and not states or
international organizations like UNAIDS. While the WMAs revision of the
Declaration of Helsinki and CIOMS' revision of its guidelines will be influ-
ential, what will matter for purposes of international law is whether states
follow or reject aspects of the revised documents. If the CIOMS revisions
support the Declaration of Helsinki (2000) in adopting a universal standard
of care, but governments in the developed and developing worlds opt for a
local standard of care in sponsoring clinical trials, then state practice and
international law will gravitate toward the local standard of care principle. A
conflict between international ethical guidelines and international law
would thus emerge.
C. Civil and Political Rights
The next question to consider in an international legal analysis of the
ethical controversy surrounding the placebo-controlled trials is what kind of
rights the controversy affects: civil and political rights, or economic, social
and cultural rights? The ethical controversy over the placebo-controlled tri-
als actually implicates both kinds of rights, and the controversy also raises
the geographical morality problem in both sets of rights. This section ana-
lyzes civil and political rights, and Part IVD below analyzes economic, so-
cial, and cultural rights.
The controversy surrounding the placebo-controlled trials implicates
three civil and political rights in international law: (1) the right to life;
(2) the right not to be subjected to medical or scientific experimentation
without the person's free consent; and (3) the right not to be subjected to
degrading treatment. 174
1. The Right to Life
Critics of the placebo-controlled trials have argued that the failure to use
the 076 regimen resulted in foreseeable, preventable deaths of children born
to the HIV-infected women. Lurie and Wolfe concluded their New England
Journal of Medicine article by referring to "hundreds of infants who have
needlessly contracted HIV infection in the perinatal-transmission studies
that have already been completed." 175 In sponsoring clinical trials that used
placebos rather than the 076 regimen, did the sponsoring and host govern-
174. See Todres, supra note 26, at 742-55. While Todres analyzes the possibility that the placebo-
controlled trials violate international law on medical experimentation, cruel or inhuman treatment, and
gross violations of internationally recognized human rights, he does not analyze whether the placebo-
controlled trials violate the international human right to life.
175. Lurie & Wolfe, supra note 15, at 855.
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ments arbitrarily deprive children of their lives in violation of the right to
life under international law?
International human rights law states that every human being has the in-
herent right to life and that no one shall be arbitrarily deprived of his or her
life.' 76 The governmental duty to protect life under international law con-
tains both negative and positive obligations. On the negative side, the right
to life, inter alia, disciplines a criminal justice system in how it applies the
death penalty. 177 The right to life is, thus, a restraint on government power
in connection with persons arrested for criminal offenses. On the positive
side, the right to life imposes on states two duties. First, states must prevent
activities that result in arbitrary deaths, such as criminal acts.17 8 Second,
states must take action to reduce or eliminate threats to human life, such as
malnutrition and infectious diseases.1 7 9
Concluding that the failure to use the 076 regimen or some other proven
intervention in the placebo-controlled trials violates the right to life in in-
ternational law is difficult for a number of reasons. The positive obligations
that the right to life imposes on governments applies to the placebo-
controlled trials. The right to life is applicable to clinical trial research be-
cause a government is responsible for making sure such research does not
result in arbitrary deaths among the research subjects. A government that
conducts or allows unregulated and dangerous clinical trials to cause arbi-
trary deaths would violate the right to life under international law.
Case law within the European Convention on Human Rights (ECHR)
supports this conclusion. In Association X v. United Kingdom, the European
Commission of Human Rights held that a government complies with its
obligation to protect life under Article 2 of the ECHR if it establishes a con-
trol and supervision system over a voluntary vaccination program to reduce
as much as possible the number of deaths that might occur.180 One may in-
terpret this case to mean that failure to regulate, control, and supervise
clinical trials to reduce the risks of research subjects would violate the right
to life under Article 2 of the ECHR. The same reasoning could apply under
Article 6 of the ICCPR and Article 6 of the United Nations Convention on
the Rights of the Child.
176. See European Convention for the Protection of Human Rights and Fundamental Freedoms, Nov.
4, 1950, art. 2(1), 213 U.N.T.S. 221 ("Everyone's right to life shall be protected by law. No one shall be
deprived of his life intentionally save in the execution of a sentence of a court following his conviction of
a crime for which this penalty is provided by law."); ICCPR, supra note 143, art. 6(1) ("Every human
being has the inherent right to life. This right shall be protected by law. No one shall be arbitrarily
deprived of his life."); United Nations Convention on the Rights of the Child, Nov. 20, 1989, art. 6(1),
28 I.L.M. 1456 (1989) ("States Parties recognize that every child has the inherent right to life.").
177 See PAUL SIEGHART, THE INTERNATIONAL LAW OF HuMtAN RIGHTS 130-31 (1983).
178. See ANNA-LENA SVENSSON-MCCARTHY, THE INTERNATIONAL LAW OF HuMAN RIGHTS AND
STATES OF EXCEPTION 406-07 (1998) (noting Human Rights Committee's interest in the positive and
negative obligations created by the right to life).
179. See id.
180. Association X v. United Kingdom, App. No. 7154/75, 14 Eur. Comm'n H.R. Dec. & Rep. 31
(1978).
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The placebo-controlled trials do not, however, fall into the category of un-
regulated or unsupervised clinical trials that caused arbitrary deaths. Both
the sponsoring and host countries reviewed the trials thoroughly before they
commenced. 8 1 To the author's knowledge, no one has criticized the spon-
soring or host governments of neglecting to monitor and supervise the pla-
cebo-controlled trials. Furthermore, the trials themselves did not directly
cause any deaths that have occurred or may occur in the future from perina-
tal HIV transmission, as HIV was already present in the pregnant women.
The most relevant category within the right to life is the governmental
obligation to reduce or eliminate threats to human life. Were the sponsoring
and host governments of the placebo-controlled trials under an international
legal obligation to reduce the threat of perinatal HIV transmission through
the use of the 076 regimen or another proven intervention rather than a pla-
cebo? An affirmative answer to this question would stress that (1) the gov-
ernments in question knew the threat of perinatal HIV transmission was
foreseeable, significant, and dangerous to the health of the child; and
(2) researchers had available a regimen proved effective elsewhere in reduc-
ing such transmission. Under this argument, failure to require use of the
076 regimen would represent a violation of the right to life of the research
subjects' children.
Cases decided by national courts support this position. In the Venezuelan
Supreme Court case, In the Matter of Cruz Bermudez v. Ministerio de Sanidad y
Asistencia Social (MSAS), 182 Venezuelan citizens living with HIV claimed
that the Venezuelan government violated, inter alia, their right to life guar-
anteed by the Venezuelan Constitution and international law by not pro-
viding them with HIV therapies. The Venezuelan Supreme Court agreed
with the plaintiffs, holding that the Venezuelan government's failure to pro-
vide HIV therapies to persons in Venezuela living with HIV violated such
persons' right to life. The Venezuelan Supreme Court wrote:
The right to life is, in fact, a positive right and not a negative right,
such as the right to liberty. It is, therefore, fundamental that the State
has public health policies. In consequence, in this case, the obligations
imposed on the public authority in matters of prevention and treatment
of HIV/AIDS are fundamental.183
181. Varmus & Satcher, supra note 50, at 1005 (arguing that "the NIH- and CDC-supported trials
have undergone a rigorous process of ethical review, including not only the participation of the public
health and scientific communities in the developing countries where the trials are being performed, but
also the application of the U.S. rules for the protection of human research subjects by relevant institu-
tional review boards in the United States and in the developing countries").
182. In the Matter of Cruz Bermudez ec al v. Ministerio de Sanidad y Asistencia Social (MSAS)
(1999), Case No. 15789, reprinted in DAVID P. FIDLER, INTERNATIONAL LAW AND PULIC HEALTH:
MATERIALS ON AND ANALYSIS OF GLOBAL HEALTH JURISPRUDENCE 316-26 (2000).
183. Id. at 321. See also Mary Anne Tortes, Access to Treatment as a Human Right: A Discussion of
the Aspects of the Right to Health Under National and International Law in Venezuela 174 (2000)
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The plaintiffs did not accuse the Venezuelan government of infecting them
with HIV (at least not in the way that, for example, government negligence
and inaction led to the infection of many hemophiliacs with HIV through
transfusions of contaminated blood). The right-to-life claim involved gov-
ernmental failure to provide an available therapy to persons living with HIV.
Access to HIV therapies was also at the center of a case brought against El
Salvador before the Inter-American Commission for Human Rights (Inter-
American Commission).18 4 Twenty-seven El Salvadoran citizens argued be-
fore the Inter-American Commission that the El Salvadoran government's
refusal to supply them with HIV therapies violated their right to life and
health under the Inter-American system of international human rights
law.18 5 The Inter-American Commission granted precautionary measures in
favor of the HIV-positive petitioners by ordering the El Salvadoran govern-
ment to provide the petitioners with the HIV therapies and other medical
treatment necessary to prevent their deaths.18 6 While not a final determina-
tion that El Salvador violated the right to life of the HIV-positive petition-
ers, the order for precautionary measures connected this international human
right to the question of access to HIV therapies187
These national and international legal precedents suggest that the spon-
soring and host governments involved in the placebo-controlled trials had a
duty under the international human right to life to provide the 076 regimen
to the research subjects in order to reduce the significant, foreseeable, and
dangerous threat of perinatal HIV transmission.
(unpublished LL.M. Thesis, University of Toronto School of Law) (on file with author) discussing a Costa
Rican Supreme Court case (William Garcia v. Caja de Salud, Sala Constitucional de la Corte Suprema de
Justicia (Costa Rica), Sept. 23, 1997) in which the Court used, among other rights, the right to life in
the Costa Rican Constitution as the basis for ordering the government to provide HIV-positive Costa
Ricans with HIV therapies.
184 See Inter-American Commission on Human Rights, Annual Report 1999, Chapter III. C.l.i,
http://www.cidh.org/annualrep/99eng/Chapter3.htm (visited Mar. 15, 2001) (describing precautionary
mesures granted in favor of HIV-positive El Salvadoran citizens).
185. Id. The right to life is protected in Article 4 of the American Convention on Human Rights,
Nov. 22, 1969, 1144 U.N.T.S. 123, 9 I.L.M. 673, [hereinafter American Convention] and Article I of the
American Declaration of the Rights and Duties of Man, May 2, 1948, O.A.S. Res. XXX, International
Conference of American States, 9th Corf., OAS Doc. OEA/Ser. LIV/I. 4 Rev. XX (1948), reprinted in
Organizaton of American States, Basic Documents Pertaining to Human Rights in the Inter-American
System, at 17, OAS Doc. OEA/Ser.L. V/I. 71, doc.6 rev.1 (1988) [hereinafter American Declaration].
The right to the preservation of health is protected in Article XI of the American Declaration, supra, and
in Article 10 of the Additional Protocol to the American Convention on Human Rights in the Area of
Economic, Social, and Cultural Rights, Nov. 14, 1988, O.A.S.T. S. 69, 28 I.L.M. 156.
186. Inter-American Commission on Human Rights, Annual Report 1999, supra note 184. Article 25
of the Rules of Procedure of the Inter-American Commission deals with Precautionary Measures and
provides that, -[i]n serious and urgent cases, and whenever necessary according to the information avail-
able, the Commission may, on its own initiative or at the request of a party, request that the State con-
cerned adopt precautionary measures to prevent irreparable harm to persons." Rules of Procedure for the
Inter-American Commissioner of Human Rights, art. 25(1), http://www.oas.org/ (visited Mar. 15, 2001).
187. As of November 2000, the El Salvadoran government had not complied with the precautionary
order of the Inter-American Commission. See discussion of this case in Torres, supra note 183, at 177-79.
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Interpreting the human right to life to require the sponsoring and host
governments of the placebo-controlled trials to administer the 076 regimen
is not, however, without problems. The first set of problems arises from the
sources of international law. Under what source of international law were the
sponsoring and host governments required to administer the 076 regimen in
the placebo-controlled trials? If the source is a human rights treaty, such as
the ICCPR or the African Charter on Human and Peoples' Rights,188 then
the obligation to administer the 076 regimen or some other proven inter-
vention must be found either in the text of the treaties or in the subsequent
practice of States Parties to the treaties. A specific duty to administer the
076 regimen or some other proven intervention as the best available treat-
ment to subjects of a clinical trial does not appear in any human rights
treaty protecting the right to life. Nor, to the author's knowledge, has such a
specific duty been produced by the subsequent practice of states under any
human rights treaty. The positive obligations created by the right to life
may make international human rights law relevant to the controversy over
the placebo-controlled trials, but they do not definitively indicate that the
sponsoring and host governments had an international legal duty to admin-
ister the 076 regimen to the research subjects.
If the source of the alleged obligation is customary international law, then
there should be general and consistent state practice supported by opinio ju-
ris. The fact that the sponsoring and host governments involved in the pla-
cebo-controlled trials did not administer the 076 regimen suggests that nei-
ther general and consistent state practice nor opinio juris exists to support an
international legal obligation always to apply the best available treatment to
research subjects. This fact relates to the disagreements that exist among
countries and experts about what the best available treatment standard re-
quires ethically in clinical trials. As UNAIDS argued in its Guidance
Document, "there is no universal consensus regarding the level of care and
treatment that should be provided."'18 9
The third primary source of international law, general principles of law
recognized by civilized nations, also has relevance in this analysis. One could
argue that international law imposes an obligation via the right to life to use
the 076 regimen as the best available treatment in clinical trials concerning
HIV perinatal transmission because that is the rule and practice in devel-
oped states. There is agreement that the 076 regimen would have been ad-
ministered to research subjects if the perinatal HIV transmission clinical
trials had taken place in the United States or Europe. As Ronald Bayer ar-
gued, "Ithere is no question that a placebo-controlled trial of efforts to re-
duce further vertical transmission in the wake of clinical trial 076 would be
188. African Charter on Human and Peoples' Rights, June 27, 1981, O.A.U. Doc.
CAB/LEG/67/3/Rev. 5, 21 I.L.M. 58 (entered into force Oct. 21, 1986).
189. UNAIDS, ETHICAL CONSIDERATIONS IN HIV PREVENTIVE VACCINE RESEARCH, supra note 64,
at 41.
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considered unethical in the United States or any advanced industrial na-
tion."' 9° Perhaps this fact indicates that there might be a general principle
of law within many national legal systems that should be elevated to the
realm of international law to regulate international clinical trials.
Problems beset this "general principle of law" argument as well. First,
general principles of law are not frequently used as a source of international
law,' 9' rendering this source suspect as a foundation for a principle supple-
menting the right to life. Second, while the practice in developed states may
be to apply the best available treatment, the situation in developing coun-
tries is different. The developing country governments hosting the placebo-
controlled trials did not require foreign and local researchers to apply the
best available treatment as a matter of domestic law. Thus, "best available
treatment," interpreted as what applies in developed countries, may not be a
general principle of national law throughout the international system.1
92
Third, it may not be true that "best available treatment" is mandated by
national law in developed states. In the United States, for example, would a
woman participating in trials equivalent to the placebo-controlled trials
have a constitutional claim that her child's right to life had been violated by
the researchers' failure to administer the 076 regimen? The answer to this
question under U.S. constitutional jurisprudence is probably negative be-
cause there is no constitutional right to any kind of medical treatment. 193
Assuming that this woman was randomly selected to receive placebo rather
than the 076 regimen, then she probably would not be able to argue that her
child's treatment constituted racial discrimination in violation of the Consti-
tution. Since only women would be research subjects in clinical trials in-
volving perinatal HIV transmission, gender discrimination is also not a
foundation for a constitutional claim. As for potential claims under federal
statutory law, federal law on the protection of human subjects does not ex-
pressly mandate a best available treatment standard.' 94
The ECHR provides a good lens through which to evaluate whether
European governments would require the best available treatment standard.
It simply is not clear from Article 2 case law under the ECHR whether fail-
ure to administer the 076 regimen would violate the right to life in a Euro-
pean country party to this treaty. While the obligation under Article 2 of
the ECHR requires governments "not only to refrain from taking life 'inten-
190. Bayer, supra note 35, at 568.
191. BROWNLIE, supra note 162, at 15-18.
192 Abdool Karim, supra note 172, at 565 (noting that standards of care "differ across the world and
even within countries; they are seldom agreed upon internationally").
193. Where a special custodial or other relationship exists between an individual and the government,
however, the government may have a duty to provide medical care. See, e.g., Estelle v. Gamble, 429 U.S.
97 (1976) (holding that denial of medical care to a prisoner constitutes cruel and unusual punishment in
violation of the Eighth Amendment to the Constitution). See also Youngberg v. Romeo, 457 U.S. 307,
115 (1982) (holding, inter alia, that an involuntarily committed mental patient has a right to medical
care under the Fourteenth Amendment Substantive Due Process Clause).
194 Protection of Human Subjects, supra note 168.
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tionally' but, further, to take appropriate steps to safeguard life," 195 the reach
of this positive obligation to safeguard life has not been the subject of much
litigation under the ECHR. An argument could be mounted that failure to
administer the 076 regimen in a European-based perinatal HIV transmis-
sion clinical trial would violate the right to life in the ECHR, but at the
moment it is not clear as a matter of international law among the States Par-
ties to the ECHR whether it would actually be a violation of Article 2.196
The second set of problems with arguing that the placebo-controlled tri-
als violated the right to life under international law is ambiguity about the
breadth of the positive obligations this right imposes on governments.
Commentators have observed that giving the right to life positive obliga-
tions for governments to fulfill brings the right close to economic, social,
and cultural rights, such as the right to health.197 As examined further be-
low in Parr IV. D, economic, social, and cultural rights are not absolute but
are achieved progressively subject to the availability of resources. Fulfillment
of the right to health therefore remains subject to the availability of
sufficient economic and human resources. Does the principle of progressive
realization affect the positive obligations of the right to life?
As a matter of treaty law, the right to life is not subject to the principle of
progressive realization because this principle is not included in treaties pro-
tecting economic, social and cultural rights. Thus, a state cannot excuse its
failure to fulfill the positive obligations of the right to life on the basis of
insufficient economic and human resources. Leaving aside the treaty argu-
ment, the principle of progressive realization does not affect the positive
obligations of the right to life in connection with the placebo-controlled
trials because the sponsoring and host governments together had enough
resources to provide the 076 regimen to the research subjects. 198 Thus, lack
of financial resources cannot be argued to excuse the sponsoring and host
governments of their positive obligations under the right to life in connec-
tion with the clinical trials. Further, this conclusion does not necessarily
imply that the sponsoring and host governments had a broader duty under
the right to life to treat all HIV-infected mothers in the host countries with
the 076 regimen as the analysis can be confined to the clinical trials.
A final analytical step involves considering whether one could argue that
the sponsoring and host governments legitimately derogated from the right
195. Association X v. United Kingdom, supra note 180, at 32.
196. The Inter-American Commission on Human Rights' precautionary measures order against the
government of El Salvador in February 2000, see supra notes 184-187 and accompanying text, also raises
the possibility that failure of the government in the Dominican Republic, which hosted a placebo-
controlled trial (and is a party to the American Convention on Human Rights), to insist on testing the
short-course AZT regimen against the 076 regimen rather than placebo constituted a violation of the
right to life in the American Convention.
197. See DOMINIC MCGOLDRICK, THE HUMAN RIGHTS COMITTrEE: ITS ROLE IN THE DEVELOP-
MENT OF THE INTERNATIONAL COVENANT ON CIVIL AND POLITICAL RIGHTS 330 (1991).
198. See Bayer, supra note 35, at 568 ("The issue is not whether the ACTG 076 would be affordable
for the very limited number of research subjects. It is.").
2001 / Placebo-Controlled HIV Clinical Trials
to life in using placebos in the clinical trials. Unlike other civil and political
rights, the right to life is not absolute. While increasingly outlawed and
opposed, 199 the death penalty remains a recognized derogation from the
right to life. Economic and human resource constraints may also create le-
gitimate derogations from the positive obligations imposed by the right to
life. In connection with the placebo-controlled trials, defenders of the trials
have variously argued that using placebos is (1) a better scientific method for
the development of new HIV therapies200 and (2) a more appropriate ap-
proach given the socio-economic realities in the host countries. 20 1 These ar-
guments legally translate into the following propositions: the right to life
may be violated in clinical trials if (1) saving an individual's life compro-
mises the scientific progress that could be made by allowing the individual
to die, and (2) the treatment used to save lives is not affordably available in
the country in question.
Both propositions turn the "geographical morality" problem into a "geo-
graphical legality" problem by suggesting that the right to life, as a matter
of international law, is not applied equally in all countries. In other words,
the content of the right to life is relative to the level of a country's level of
economic development. This perspective causes problems under interna-
tional law because civil and political rights, such as the right to life, are to
be secured without discrimination on any ground, including race, national
origin, wealth, birth, or other status.20 2 Allowing governments to derogate
from the right to life on socio-economic grounds is discrimination on the
basis of economic status and is not allowed by international human rights
law. This again raises the question why economic-status discrimination is
defended by some in the ethical debates about the placebo-controlled trials.
We seem to be back to the problem of "geographical morality" via interna-
tional human rights law.
In addition, the argument that the right to life was violated could be
supported by the principle in Article 3 of the United Nations Convention
on the Rights of the Child:
In all actions concerning children, whether undertaken by public or
private social welfare institutions, courts of law, administrative authori-
ties or legislative bodies, the best interests of the child shall be a pri-
mary consideration. 2° 3
199. See, e.g., Protocol No. 6 to the Convention for the Protection of Human Rights and Fundamental
Freedoms Concerning the Abolition of the Death Penalty, E.T.S. 114, entered into force Mar. 1, 1985, 22
I L.M. 539 (1983), http://conventions.coe.int/treatylEN/cadreprincipal.htm (visited Mar. 15, 2001).
200. See Varmus & Satcher, supra note 50, at 1004-05.
201. Levine, supra note 35, at 533-34.
202. See ICCPR, supra note 143, art. 2(1).
203. Convention on the Rights of the Child, supra note 176, art. 3(1).
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It is simply not plausible to argue that it was in the best interests of the
children born to the HIV-infected women in the placebo-controlled trials to
deny them the benefits of the 076 regimen.
Defenders of the placebo-controlled trials respond by emphasizing the
brutal facts about the poor condition of public health in developing coun-
tries. Robert Levine argues that asserting that the 076 regimen should have
been used without also requiring the provision of infant formula (to prevent
HIV transmission through breast feeding) and purified water (to prevent
infant formula from causing diarrheal diseases from contaminated water) is
inconsistent.20 4 Levine's arguments underscore the uncertainty about the
scope of the positive obligations ostensibly required by the right to life as
supplemented by the principles of non-discrimination and the best interests
of the child. For Levine, economic reality imposes geographical morality on
the international research community:
It is necessary to acknowledge with regret that there are great imbal-
ances in the distribution of wealth among the nations of the world. De-
veloping countries that cannot afford all the goods and services to pro-
mote health care that are available to residents of industrialized nations
must be allowed to develop treatments and preventive interventions
that they can afford. Research sponsors, both industrial and governmen-
tal, in industrialized countries should not be prevented from assisting
developing countries in their efforts in this regard.20 5
What this complicated analysis of the right to life suggests is that it is
plausible under international human rights law to argue that the sponsoring
and host governments violated the right to life in not administering the 076
regimen to all research subjects in the placebo-controlled trials. While the
argument is plausible, however, it gets ahead of where international law on
the right to life actually is today. At the very least, this analysis suggests
that the controversy over the placebo-controlled trials raises important and
unresolved issues in connection with the fundamental human right to life in
international law. In addition, the analysis indicates that, for those who be-
lieve that the placebo-controlled trials were unethical, there is an opportu-
nity to push this controversy onto the agenda of international human rights
law and perhaps refine further the positive obligations triggered by the right
to life. The principle of non-discrimination would support such an effort.
But this effort would quickly confront the question how far the positive
obligations under the right to life extend in the context of clinical trials in
developing countries. As Levine's analysis suggests, the broader these posi-
tive obligations, the more unrealistic the clinical trials become in connection
with providing affordable, sustainable interventions for developing coun-
204. Levine, supra note 35, at 533.
205. Id. at 534.
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tries. The positive protections of the right to life could be clarified and uni-
versalized, but would the long-run result be higher numbers of deaths be-
cause the universalization of the human right prevented tangible progress on
treating dreaded diseases in the developing world? Would such a result be
ethically and legally correct, or a product of ethical and legal imperialism?
2. Right of Free Consent to Medical or Scientific Experimentation
International law prohibits governments from conducting medical and
scientific research on individuals without their free consent.206 Conceptually,
the right of free consent connects with the more general human right of se-
curity of person.20 7 The right to free consent arose in international law to
prohibit the kind of medical and scientific experiments conducted by Nazi
and Japanese doctors and scientists on prisoners of war and those interned in
concentration camps. 20 8 These atrocities were also the direct source of the
Nuremberg Code's first principle that "tt]he voluntary consent of the human
subject is absolutely essential. '20 9 The growth of peaceful clinical research on
medicines for infectious and non-communicable diseases in the post-Second
World War period gave the right of free consent a central role in medical
and scientific progress against diseases.
As noted earlier, critics of the placebo-controlled trials have argued that
these trials violate the ethical principle of free consent because of the desper-
ate medical and socio-economic condition in which the pregnant women in
the host countries found themselves. 210 These accusations connect with long-
standing concerns about the application of the free consent principle in poor
countries.211 The right of free consent has proven difficult to implement in
developing countries because the cultures in many of these countries do not
adhere to the liberal concept of individual rights. The notion of an individ-
ual freely granting consent to medical or scientific research may have been
206. See ICCPR, supra note 143, art. 7 ("[N]o one shall be subjected without his free consent to medi-
cal or scientific experimentation."); Convention for the Protection of Human Rights and Dignity of the
Human Being with Regard to the Application of Biology and Medicine, Apr. 4, 1997, Europ. T. S. No.
164, art. 5 [hereinafter European Bioethics Convention] ("An intervention in the health field may only be
carried out after the person concerned has given free and informed consent to it. This person shall before-
hand be given appropriate information as to the purpose and nature of the intervention as well as on its
consequences and risks. The person concerned may freely withdraw consent at any time.").
207. ICCPR, supra note 143, art. 9(1).
208. See, e.g., THE NAZI DOCTORS AND THE NUREMBERG CODE: HUMAN RIGHTS IN HuMAN Ex-
PERiMENTATION (George J. Annas & Michael A. Grodin eds., 1992); PETER WLLIAsMS & DAVID
WALLACE, UNIT 73 1: JAPAN'S SECRET BIOLOGICAL WARFARE IN WORLD WAR II (1989).
209. Nuremberg Code, supra note 30, princ. 1.
210 See Annas & Grodin, supra note 25, at 562; see also Todres, supra note 26, at 757-58 (analyzing
whether informed consent was obtained in drug trials and arguing that it would require detailed eviden-
tiary examination at a trial to determine whether such consent was obtained); Jay Dyckman, The Myth of
Informed Consent: An Analysis of the Doctrine of Informed Consent and Its (Mis)Application in HIV Experiments
on Pregnant Women in Developing Countries, 9 COLUM. J. GENDER & L. 91 (1999).
211. See LAWRENCE GOSTIN & ZITA LAZZARINI, HuseAN RIGHTS AND PUBLIC HEALTH IN THE AIDS
PANDEMIC 15 (1997).
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alien to the cultures in which the placebo-controlled trials took place. 21 2 In
addition, medical and scientific researchers have confronted problems in ob-
taining "free consent" in developing countries because the low level of edu-
cation among research subjects makes it difficult to determine whether a
person fully understands to what he or she is giving consent. 213 In this situa-
tion, cultural diversity complicates ethical and international legal applica-
tion of the right to free consent.
To the author's knowledge, the right of free consent has not been the
subject of claims before international human rights bodies in connection
with the conduct of clinical trials, so there are no precedents to assist inter-
national legal analysis. (The right of free consent has been implicated in the
use of medical treatment against political prisoners in connection with alle-
gations of torture and inhuman or degrading punishment or treatment. 214)
Analysis of the right of free consent in the clinical trial context cannot have
as its objective the determination that the person in question really gave full,
informed, and free consent. 21 5 This kind of subjective test would prove im-
possible to implement as a practical matter. Instead, whether the right of
free consent has been violated has to be determined according to objective,
procedural standards.216 First, evidence must exist that the person in ques-
tion was fully informed by the researchers of the risks of participating in the
research. 217 Second, evidence must be presented that the person gave his or
her consent.218 Third, the context in which the consent was given must be
free of duress or pressure applied or created by the researchers. 219
This analytical framework does not eliminate all difficult questions cre-
ated by the right of free consent in the context of cultural diversity. Can, for
212. See RuTH MACKUN, AGAINST RELATIVISM: CuLTuRAL DIVERSITY AND THE SEARCH FOR ETHI-
CAL UNIVERSALS IN MEDICINE 190 (1999) (noting that "some researchers in non-Western countries have
complained that it is 'ethical imperialism' to impose North American procedures requiring strict adher-
ence to informed consent on cultures in which patients normally do not have to give consent to treatment
or research maneuvers").
213. Todres, supra note 26, at 757 ("In a number of research studies in developing countries, the
population from which the research subjects are drawn consists largely of low- or uneducated, and some-
times illiterate, individuals.").
214. See NIGEL S. RODLEY, THE TREATMENT OF PRISONERS UNDER INTERNATIONAL LAw 232-35
(1987) (discussing medical or scientific experimentation and treatment on prisoners).215. But f Todres, supra note 26, at 758 (noting that "one must wonder whether a team of foreign
researchers that has the additional burden of overcoming cultural barriers is capable of obtaining truly
informed consent from the research subjects").
216. Lackey argued similarly when he stated that "the old requirement that consent should be volun-
tary and informed be replaced by a new requirement that consent should be uncoerced and undeceived."
Lackey, supra note 19, at 10. Lackey's reformulation of the free consent principle places the focus on what
the researchers do rather than on whether the research subject really understood the consent process or
the clinical trial. Lackey further argued: "Coercion in research is morally wrong; deception in research is
morally wrong. The consent process must rule them out. But the inability of subjects to comprehend the
derails of the consent process is not so much a moral issue as a fact of life." Id.
217. Protection of Human Subjects, supra note 164, § 46.116 (General Requirements for Informed
Consent); see also European Bioethics Convention, supra note 206, art. 16(iv).
218. European Bioethics Convention, sopra note 206, art. 16(v).
219. See id. art. 5.
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example, the consent of a tribal or community leader substitute for individ-
ual consent under international law? The answer to that question under in-
ternational law is probably in the negative and that the individual's consent
has to be obtained. If the individual will not give his or her consent without
permission from the community leader, then such permission is an impor-
tant condition to the individual's consent, but it cannot be a substitute. Cut-
ting the individual out of the consent procedure would not be acceptable
under international human rights law. This conclusion made proposed revi-
sions of the Declaration of Helsinki (1996) that would have diluted the
principle of free consent alarming from not only an ethical perspective but
also an international legal perspective. 220
The placebo-controlled trials did not, however, involve the disregard of
individual consent. 221 The arguments about the right to free consent in con-
nection with these trials do not involve accusations that the researchers
failed to inform the research subjects of the risks or that the research sub-
jects' consent was not obtained. 222 The arguments concentrate on the third
test mentioned above by asserting that the context in which the clinical tri-
als took place tainted the consents that were obtained. In other words, the
consent of pregnant African women infected with HIV to participate in the
clinical trials was not freely given in a substantive rather than procedural
sense because of the desperate health situation these women faced.223 Their
socio-economic condition acted as a coercive force in the consent process that
the researchers did not create but of which they took advantage.
Under international human rights law, the context of medical or scientific
treatment or experimentation is important. In connection with the right of
free consent in Article 7 of the ICCPR, the Human Rights Committee has
stated "that special protection in regard to such [medical and scientific] ex-
periments is necessary in the case of persons not capable of giving valid con-
sent, and in particular those under any form of detention or imprison-
ment."224 The right of free consent applies to fully autonomous persons, but
220. See Letter to Human, supra note 65 (arguing that "the proposed Declaration, by creating a set of
glaring loopholes in the informed consent requirements, is the first significant step backward in the
evolution of informed consent guidelines"). The World Medical Association apparently strengthened the
revised Declaration of Helsinki in a subsequent revised proposal. See Letter to Human (July 31, 2000),
saipra note 65.
221 See Varmus & Satcher, supra note 50, at 1004.
222. Public Citizen did, however, demand to see the individual consent documentation from the pla-
cebo-controlled trials. Press Release, Public Citizen, Health Group Files Suit Over NIH Experiments on
HIV-Posirive Women in Developing Countries: NIH Fails to Produce Consent Forms and Other Docu-
ments for Unethical Experiments on Pregnant Women (Mar. 18, 1998) (stating that the NIH was un-
willing or unable to produce the consent forms supposedly completed by the subjects of the placebo-
controlled trials), http://www.citizen.org/presslpr-sid-4.htm (visited Mar. 15, 2001); see also Letter to
Shalala, supra note 29 ("We have not yet obtained the informed consent forms for these studies, and so it
is conceivable that additional principles of the (Nuremberg] code have not been followed and that the
studies are therefore even more unethical than we state here.").
223 See Annas & Grodin, supra note 25, at 562.
224. Svensson-McCarthy, supra note 178, at 429.
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what the Human Rights Committee stresses is the need for extra vigilance
in connection with vulnerable people. Traditionally in international human
rights law, that vulnerability has arisen in connection with involuntary de-
tention or imprisonment. The research subjects of the placebo-controlled
trials were not involuntarily detained or imprisoned, but their socio-
economic condition made them vulnerable.
Vulnerability does not, however, mean that a person cannot give free con-
sent within the meaning of that right under international law. Vulnerability
is a warning for, not an absolute bar to, medical and scientific experimenta-
tion. The European Bioethics Convention's rules on free consent address the
protection of persons not able to consent (i.e., minors, the mentally ill, and
those in the midst of a medical emergency), 225 but it does not contain rules
about dealing with socio-economic vulnerability of research subjects. Nor
can any such rules be found in other treaties. The Declaration of Helsinki
(2000) states:
The particular needs of the economically and medically disadvantaged
must be recognized. Special attention is also required for those who
cannot give or refuse consent for themselves, for those who may be
subject to giving consent under duress, for those who will not benefit
personally from the research and for those for whom the research is
combined with care.22
6
National laws sometimes contain the principle that additional safeguards
are needed in research projects including physically, economically, or educa-
tionally disadvantaged persons in order to protect the rights and welfare of
such persons.227 Assuming that this principle of extra safeguards for eco-
nomically or educationally disadvantaged persons appeared generally and
consistently in state practice with the requisite opinio juris, then a rule of
customary international law exists. But this rule would not prohibit in-
volving persons in bad socio-economic conditions in medical and scientific
research because it only requires extra care and diligence on the part of gov-
ernments sponsoring such research. 228
It is also not apparent whether a stricter, prohibitory rule should be de-
veloped to address the problem perceived to be caused by bad socio-
225. European Bioethics Convention, supra note 206, arts. 6-8.
226. Declaration of Helsinki (2000), supra note 72, princ. 8.
227. Protection of Human Subjects, supra note 164, subparts B (additional protections pertaining to
research involving fetuses, pregnant women, and human in vitro fertilization), C (additional protections
pertaining to research involving prisoners as subjects), and D (additional protections for children in-
volved as subjects in research).
228. Lackey, supra note 19, at 9, writes:
It is ... a principle of both law and morals that persons cannot be held to contracts made from des-
peration. It would follow, then, that these subjects could not be held to any agreements made upon
entering into the studies, a consideration guaranteed in any event by the rule of research ethics that
every subject is free to withdraw without penalty at any time.
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economic conditions. First, to assume someone in poor socio-economic con-
ditions is incapable of giving free and informed consent cuts into the core
assumptions of the right of free consent: that each individual is autonomous
and capable of individual self-determination. 229 Second, assuming someone
in poverty is not capable of giving consent is akin to treating them like
children or the mentally ill, which again is antithetical to the norms of
autonomy and self-determination informing the right of free consent.
Third, determining how much socio-economic deprivation would be nec-
essary to vitiate the right of free consent would be fraught with subjectivity.
Fourth, such subjective line-drawing seems ill-designed to be able to pro-
duce consensus among states through the mechanisms of treaty law or cus-
tomary international law. Fifth, determining that a certain level of socio-
economic deprivation renders an individual incapable of giving free consent
is prima facie discrimination on the basis of economic status in violation of
the fundamental human rights principle of non-discrimination.
For these reasons, believing that states through international law have
taken or will take away the right of free consent from individuals in poor
socio-economic conditions and thus cut off access to them for medical and
scientific researchers is neither factually persuasive nor normatively attrac-
tive. Critics of the placebo-controlled trials are right to point out the vul-
nerability of the developing-country populations in the context of HIV ther-
apy clinical trials, but international law provides no support for terminating
clinical research in developing countries because of such vulnerability. In
addition, this international legal analysis bolsters ethical opposition to pro-
posed changes in international ethical guidelines that dilute the principle of
free consent.
This analysis of the right of free consent shows the strains exhibited by
solidaristic rationalism in action outside the core. The entire edifice of inter-
national law on the right of free consent is built on Western liberalism's as-
sumptions and beliefs about individuals. Such assumptions and beliefs work
well within the solidaristic core. But when the right of free consent comes to
Africa, for example, cultures clash. The dogmatic insistence that individual
consent be obtained in clinical trials undertaken in cultures that do not con-
ceive of individuals as autonomous and self-determining is the imposition of
the core on the periphery. Liberal revolutionism supports such an imposition
because of its belief in the unity of humankind. With the right of free con-
sent, the geographical morality problem is not one of intent but of conse-
quences. Applied beyond the solidaristic core, the right of free consent un-
derscores the hegemony of the core and the lack of autonomy and self-
determination suffered by the periphery. With regard to the free consent
principle, both proponents and opponents of the placebo-controlled trials are
229 Id. ("The crucial moral point is not whether desperation is present, but whether the presence of
desperation signifies an absence of consent ... Among ethicists, there is not consensus that desperation
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simply talking over the heads of the African women they profess to respect.
In the background, the realist watches the debate and concludes that inter-
national law, even on human rights, reflects power and its exercise in inter-
national relations.
3. The Right Not To Be Subjected to Degrading Treatment
Both treaty law and customary international law prohibit torture and
cruel, inhuman, and degrading punishment or treatment of individuals by
governments. 230 This prohibition involves levels of government misconduct,
with torture constituting the most serious and degrading treatment the least
serious. This section analyzes whether the failure of the sponsoring and host
governments to administer the 076 regimen to all research subjects in the
placebo-controlled trials constituted degrading treatment under interna-
tional human rights law.
Raising this particular civil and political right may be offensive to sup-
porters of the placebo-controlled trials. Torture and other forms of cruel,
inhuman, and degrading punishment and treatment are endemic in the in-
ternational system,231 and to lump the placebo-controlled trials with atroci-
ties such as these demeans the suffering of the victims of such gross viola-
tions of a fundamental civil and political right and grossly misrepresents
what took place in the placebo-controlled trials. While understandable, hos-
tility towards raising the prohibition against degrading treatment in con-
nection with the placebo-controlled trials does not settle the issue. 23 2 In fact,
a 1997 case decided by the European Court of Human Rights provides some
support for applying the right not to be subject to degrading treatment of
the placebo-controlled trials.
In Case of D. v. United Kingdom, a citizen of the island of St. Kitts, who
was suffering from AIDS, argued that his deportation by the United King-
dom to St. Kitts would constitute cruel, inhuman, or degrading treatment
or punishment because he would not receive adequate AIDS treatment in St.
Kitts, which would hasten his death.233 D had been arrested and imprisoned
in the United Kingdom for drug trafficking, and he had also been in the
United Kingdom illegally.234 The European Court of Human Rights re-
230. See ICCPR, supra note 143, art. 7; United Nations Convention against Torture and Other Cruel,
Inhuman or Degrading Treatment or Punishment, Dec. 10, 1984, 1465 U.N.T.S. 85, 23 I.L.M. 1027
(entered into force June 26, 1987), for treaty law. For the prohibition of torture as a rule of customary
international law, see Filartiga v. Pefia-Irala, 630 E2d 876 (2d Cir. 1980) and Regina v. Bow Street Metro.
Stipendiary Magistrate, ex parte Pinochet Ugarte, [1999) 2 W.L.R. 827 (H.L.) (24 Mar. 1999), reprinted in
38 I.L.M. 581.
231. See Press Release, Amnesty International, Fighting Torture-A Global Problem, A Common
Goal,(June 25, 1999) (stating that "all over the world, people continue to be tortured on a large scale...
in 125 countries worldwide").
232. See, e.g., Todres, supra note 26, at 752-55 (analyzing the relevance of prohibition against cruel or
inhuman treatment in connection with the placebo-controlled trials).
233. Case ofD. v. United Kingdom, 24 Eur. Cr. H.R. 423,445 (1997).
234. Id. at 447.
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ceived evidence that showed AIDS therapies and adequate medical treat-
ment for opportunistic infections would not be available to D in St. Kitts
because of the poor condition of its health care system. 235 The European
Court of Human Rights ruled that D's deportation by the United Kingdom
to St. Kitts would constitute cruel, inhuman, or degrading treatment or
punishment within the meaning of Article 3 of the ECHR.
236
In making this ruling, the European Court of Human Rights acknowl-
edged that (1) D had violated the law of the United Kingdom;237 (2) the
British government had treated and cared for D's AIDS-related health prob-
lems; 238 and (3) the United Kingdom was not responsible for the poor con-
dition of the St. Kitts health care system. 239 Nevertheless, the European
Court of Human Rights ruled against the United Kingdom in this case. The
Court stressed that it considered important the fact that D's health condi-
tion was deteriorating rapidly.24° But more important than the particular
facts of this case was an underlying principle of international human rights
law. Critical to the European Court of Human Right's ruling was its posi-
tion that the right not to be subject to cruel, inhuman, or degrading treat-
ment or punishment is an absolute right against which no derogation shall
be permitted. 24 1 Under the ECHR, the United Kingdom would violate the
treaty by acting in a way that would forseeably hasten a person's death from
AIDS, even when the death would occur in another country and the United
Kingdom was not responsible for the underlying cause of death. The Euro-
pean Court of Human Rights advanced human rights universalism in how it
dealt with the case.
Case of D. v. United Kingdom provides an intriguing backdrop against
which to analyze whether the placebo-controlled trials constituted degrad-
ing treatment in violation of international law. The sponsoring and host
governments involved in the placebo-controlled trials acted in a way that
would foreseeably lead to the death of children born to HIV-infected
women. The sponsoring and host governments had an alternative choice-
using the 076 regimen rather than a placebo-that would have saved lives.
How different is the situation of African children born with HIV from the
situation in which D found himself?.
235 Id. at 430.
236 Id. at 454.
237. Id. at 447.
238. Id. at 448-49.
239. Id. at 449.
240. Id. at 448.
241 Id. at 447. See also European Convention on Human Rights, supra note 176, art. 15(2) (providing
that no derogation from Article 3's prohibition on torture or inhuman or degrading treatment is allowed
during time of war or public emergency threatening the life of the nation); ICCPR, supra note 143, art.
4(2) (providing that no derogation from Article Ts prohibition on torture and inhuman or degrading
treatment and protection of the right to free consent to medical experimentation is allowed in time of
public emergency threatening the life of the nation).
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An analysis of whether the placebo-controlled trials constituted degrading
treatment under international law does, however, have to grapple with fac-
tual differences between D's situation and that of the placebo-controlled
trials. The placebo-controlled trials did not take place in a State Party to the
ECHR while D was being held in custody in the United Kingdom. As a
matter of treaty law, Case ofD. v. United Kingdom's interpretation of Article 3
of the ECHR does not apply to developing states that hosted the placebo-
controlled trials.242
Whether customary international law binding on all sponsoring and host
governments reflects the holding in Case of D. v United Kingdom is doubtful.
At most, customary international law prohibits the denial of medical treat-
ment to persons deprived of their liberty by a government in connection
with the operation of its criminal justice or mental health system. The
holding in Case of D. v. United Kingdom was unusual even in terms of ECHR
jurisprudence, suggesting that it is not supported by general and consistent
state practice and opinio juris.
A second fundamental difference between Case of D. v. United Kingdom and
the placebo-controlled trials is that D had been deprived of his liberty by
the United Kingdom government. None of the research subjects in the pla-
cebo-controlled trials were detained by their governments to participate in
the trials. They participated voluntarily and gave their consent. It is hard to
comprehend that the research subjects gave free consent to degrading treat-
ment within the context of international human rights law.
For argument's sake, assume that the placebo-controlled trials took place
in a State Party to the ECHR and not in developing countries. Would the
governments sponsoring and hosting the clinical trials have engaged in de-
grading treatment of research subjects who received the placebo within the
meaning of Article 3 of the ECHR? I think the answer to this question is
negative mainly because the research subjects are not deprived of their lib-
erty and thus become especially vulnerable to government mistreatment.
Arguing that the research subjects receiving the placebo had been subject to
degrading treatment would be tantamount to asserting that all HIV-infected
pregnant women in the country in question received degrading treatment
because they do not receive therapies to prevent perinatal HIV transmission.
Lack of access to government-supported public health and health care facili-
ties and services is not degrading treatment within the meaning of interna-
tional human rights law.
242. Vienna Convention on the Law of Treaties, May 23, 1969, 1155 U.N.T.S. 331, art. 34 ("A treaty
does not create either obligations or rights for a third State without its consent.").
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D. Economic, Social, and Cultural Rights: The Right to Health
The controversy over the placebo-controlled trials implicates the right to
health, one of the economic, social, and cultural human rights.243 The argu-
ment here is that the failure to use the 076 regimen or other proven inter-
vention rather than a placebo deprived the children born to HIV-infected
women in the host developing countries of their right to health.
Two central complexities arise in connection with such an argument.
First, who is under this international legal duty, and to whom is the duty
owed? Second, what is the scope of the duty? Human rights rhetoric claims
that economic, social, and cultural rights are universal and have equal im-
portance with civil and political rights,244 which suggests that all states are
under a duty to fulfill the rights to health. Economic, social, and cultural
rights have not, however, been as firmly established under international law
as the civil and political rights discussed earlier.245 The United States has,
for example, been historically hostile to economic, social, and cultural rights
generally,246 and the right to health specifically.247 European states have been
less antagonist toward economic, social, and cultural rights (see, e.g., the
European Social Charter 248 ), but these rights have been overshadowed in
European practice by civil and political rights, which are enshrined in the
ECHR. Thus, arguments that the United States and other developed-
country sponsors of the placebo-controlled trials violated the children's
rights to health confront a difficult international legal context because of the
political controversy that surrounds the right to health.
The rare cases in which an international body has addressed the right to
health provide little in the way of support for the argument that the pla-
cebo-controlled trials violated the right to health of the children born to the
HIV-infected women. In the Status of the Yanomami Indians case, the Inter-
American Commission on Human Rights found that Brazil had violated the
right to health in the American Declaration of Human Rights by exposing
243 See generally BRIGIT C.A. TOEBES, THE RIGHT TO HEALTH AS A HUMAN RIGHT IN INTERNA-
TIONAL LAW (1999); GOSTIN & LAZZARINI, supra note 270, at 27-30; FIDLER, INTERNATIONAL LAW AND
INFECTIOUS DISEASES 179-97 (1999); Patrick A. Molinari, The Right to Health: From the Solemnity of
Declarations to the Challenges of Practice, 49 INT'L DIG. HEALTH LEGIS. 41 (1998); Aart Hendriks, The
Right to Health in National and InternationalJurisprudence, 5 EUR. J. HEALTH L. 389 (1998); see also Com-
mittee on Economic, Social, and Cultural Rights, Draft General Comment No. 14: The Right to the
Highest Attainable Standard of Health (Art. 12), Version of Mar. 23, 2000 [hereinafter Draft Comment
on the Right to Health].
244. See Vienna Declaration and Programme of Action, supra note 140, at 5 ("All human rights are
universal, indivisible, and interdependent and interrelated.").
245 See MATTHEW C.R. CRAVEN, THE INTERNATIONAL COVENANT ON ECONOMIC, SOCIAL, AND
CULTURAL RIGHTS: A PERSPECTIVE ON ITS DEVELOPMENT 10 (1995) ("In the majority of States, eco-
nomic, social, and cultural rights are almost entirely absent from the common discourse on human
rights "),
246. The United States is not, for example, a party to the ICESCR.
247. Virginia A. Leary, The Implications of a Right to Health, in HUMAN RIGHTS IN THE TWENTY-FiRST
CENTURY 481, 486 (K.E. Mahoney & P. Mahoney eds., 1993).
248. European Social Charter, Oct. 18, 1961, 529 U.N.T.S. 89.
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the Yanomami Indians to epidemic diseases through deforestation of the
Amazon. 249 In this case, the Brazilian government was responsible for cre-
ating or allowing the environmental degradation in its territory that pro-
duced outbreaks of infectious diseases among the Yanomami. These facts
bear no resemblance to the placebo-controlled clinical trials.
In the Ache Tribe Case, the Inter-American Commission on Human Rights
held that Paraguay violated the right to health in the American Declaration
on Human Rights by failing to provide the Ache Indians in its territory
proper immunization against and treatment for infectious diseases. 250 The
Inter-American Commission indicated that the failure was discriminatory in
effect against the Ache Indians. The Inter-American Commission seems to
have assumed that such immunizations and treatment were within the
financial means of the government of Paraguay. In the case of the placebo-
controlled trials, no one has suggested the host governments acted discrimi-
natorily against any racial or ethnic group or had sufficient financial re-
sources to pay for the 076 regimen.
To employ the Ache Tribe Case as a precedent against the placebo-
controlled trials, one would have to argue that the sponsoring governments,
such as the United States, discriminated against the children born to the
HIV-infected women and had sufficient resources to use the 076 regimen
rather than a placebo. Given that all the children borne to women partici-
pating in the clinical trials were nationals of the country hosting the trials,
discrimination within the research group does not seem to have been a fea-
ture of the clinical trials. While the sponsoring governments had resources
to pay for or obtain the 076 regimen for all women participating in the
clinical trials, the clinical trials were not public health programs for the
general population. The facts of the Ache Tribe Case, like those of the Yano-
mami Tribe Case, are not consonant with the facts of the placebo-controlled
trials.
Uncertainty about the scope of economic, social, and cultural rights com-
pounds the problems with the right to health. All economic, social, and cul-
tural rights are subject to the principal of progressive realization, which
means that the substance of the rights varies according to the economic re-
sources available to the government. 251 Under international law, then, the
substance of the right to health is not universal but is expressly relative to a
given country's level of economic resources.
249. Case 7615, Inter-Am.C.H.R. 24, OEA/Ser.IV/II.66, doc. 10 rev. 1 (1985) (Annual Report
1984-85).
250. Case 1802, Inter-Arn.C.H.R. 36, OEAJSer.LIV/II.43, doc. 21 (1977) (Ten Years of Activities
1971-81).
251. ICESCR, supra note 144, art. 2(1) ("Each State Party to the present Covenant undertakes to take
steps, individually and through international assistance and co-operation, especially economic and tech-
nical, to the maximum of its available resources, with a view to achieving progressively the full realiza-
tion of the rights recognized in the present Covenant by all appropriate means, including particularly the
adoption of legislative measures.").
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This "progressive realization" dynamic appeared in a South African Con-
stitutional Court case that required the Court to interpret the right to health
under the South African Constitution. Section 27(1) of the South African
Constitution provides that "[elveryone has the right to have access to
(a) health care services .... -252 Section 27(2) provides that "[t]he state must
take reasonable legislative and other measures, within its available resources,
to achieve the progressive realization of each of these rights."'253 Section
27(3) provides that "[n]o one may be refused emergency treatment."254 In
Soobramoney v. Minister of Health (Kwazulu-Natal),255 the plaintiff argued that
his right to emergency treatment and right to access to health care services
were violated by a hospital's refusal to make renal dialysis available to
him.256 The plaintiff was in the final stages of chronic renal failure, and renal
dialysis would have prolonged his life. The South African Constitutional
Court ruled that the plaintiff's medical situation did not constitute an emer-
gency, so Section 27(3) did not apply.257 The Court then held that the South
African government's obligations under 27(1) are qualified by Section
27(2)'s recognition of financial constraints.258 The right to access to health
care services is expressly limited by the lack of available resources.
Occasionally national courts have rejected lack of financial resources as an
excuse for the government's failure to provide health services. 259 The Vene-
zuelan Supreme Court case noted earlier, In the Matter of Cruz Bermudez, in-
volved the Court rejecting the government's defense of scarce resources to
allegations of violations of the right to health in connection with access of
persons living with HIV to HIV therapies. 260 The Supreme Courts of Costa
Rica and Mexico similarly found their respective governments in violation of
a constitutional right to health in not supplying HIV-positive citizens with
HIV therapies. 261 But trying to discern from these cases the core content of
the right to health against which budgetary scarcity cannot be argued proves
difficult in international law.
Efforts to give the right to health some minimum core meaning that ap-
plies universally have not so far borne fruit in international law. In fact, ar-
guing that there is a minimum core meaning to the right to health in inter-
national law that is not subject to the principle of progressive realization is
252. S. AFR. CONST., ch. 2, § 27(1) (adopted May 8, 1996).
253. Id, § 27(2).
254 Id, § 27(3).





259. See Hendriks, supra note 243, at 394-402.
260. In the Matter of Cruz Bermudez, supra note 182, at 325.
261. See Torres, supra note 183, at 174-75 (discussing the Costa Rican and Mexican constitutional law
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not credible.262 The principle of progressive realization has always accompa-
nied the right to health in all treaties in which the right is embedded. Un-
der principles of treaty interpretation, it is not possible to prevent the prin-
ciple of progressive realization from applying to the elements of a minimum
core meaning for the right to health. The general rule of treaty interpreta-
tion is to interpret treaties "in good faith in accordance with the ordinary
meaning to be given to the terms of the treaty in their context and in light
of its object and purpose. ' '263 Interpretation can also be assisted by subse-
quent practice between States Parties to the treaty as to the meaning of a
treaty term.264 Both the texts of treaties including the right to health and
subsequent state practice under them do not support removing the principle
of progressive realization from some core set of health services that must in
all cases be provided by a government. 265
Thus, the scope of the right to health remains indeterminate in interna-
tional law.266 It is therefore hard to maintain that the failure of the sponsor-
ing and host governments to use the 076 regimen rather than placebo con-
stitutes a violation of the right to health. It is clear that the right to health
under international law does not require governments to provide expensive
HIV therapies to all persons living with HIV/AIDS.267 Further, arguing that
participation in clinical trials somehow triggers a more protective right to
health for research subjects than members of the general population has no
basis in contemporary international law.
The right to health is expressly a plan of geographical morality and legal-
ity. Under international law, the principle of progressive realization makes
the right to health relative to a country's level of economic development and
how it prioritizes public health and health care in an environment of scarce
resources. No moral or legal standard exists that gives the right to health
universal meaning. Although support exists for protecting some minimum
core from the impact of the principle of progressive realization, this support
has not had definitive impact on treaty law or customary international law
on the right to health. The right's place in international law is precarious,
which makes it a weak international legal basis from which to attack the
placebo-controlled trials.
262. See, e.g., TOEBES, supra note 243, at 275-84 (proposing a core content for the right to health).
263. Vienna Convention on the Law of Treaties, supra note 242, art. 31(1).
264. Id. art. 31(3)(b).
265. See FIDLER, supra note 182, at 307.
266. See Katarina Tomasevski, Health, in 2 UNITED NATIONS LEGAL ORDER 859, 873 (0. Schachter &
C.C. Joyner eds., 1995) (arguing that "the right to health has not conceptually progressed from the time
it was first proclaimed, not even to define the core terms health and righi in the proclaimed right to
health").
267. The South African, Venezuelan, Costa Rican, and Mexican cases mentioned earlier were based on
constitutional law, not international law. Even so, these cases might be seen as evidence of state practice
for purposes of customary international law analysis in connection with the right to health. More relevant
to international legal analysis will be whether the Inter-American Commission on Human Rights makes
a final determination on the right to health in connection with El Salvador's failure to provide HIV-
positive citizens with HIV therapies.
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E. Does the Double Standard Violate the Principle of Nondiscrimination in
International Law?
One of the bedrock principles of international human rights law is non-
discrimination in the enjoyment of all human rights.268 In connection with
the controversy over the placebo-controlled trials, Ronald Bayer asked "can
it be considered ethical to provide placebos to women in Uganda when do-
ing so would constitute an outrage in Brooklyn?" 269 This question raises the
issue whether the "double standard" seen at work in the placebo-controlled
trials constituted discrimination against people living in developing coun-
tries.
In order to determine whether the trials involved discrimination in viola-
tion of international human rights law, one must first identify the specific
human rights enjoyed by the research subjects in the clinical trials. The
principle of non-discrimination is not a mandate for governments to treat all
people the same in every situation; it protects the equal enjoyment of
specific human rights. Thus, the argument that immigration restrictions
against persons with HIV/AIDS violate international human rights law be-
cause such restrictions discriminate on the basis of serologic status 270 is not
persuasive because no person has a human right to enter other countries
freely.271 Similarly, for the principle of non-discrimination to apply in the
context of the placebo-controlled trials, the research subjects provided pla-
cebos must first show that the researchers and participating governments
violated a specific human right to which the non-discrimination attaches. As
analyzed in Part IV, research subjects who received the placebo rather than
AZT will have a very hard time showing that any human right recognized
in international law was violated.
V. CONCLUSION: THE PROBLEM OF GEOGRAPHICAL MORALITY AND THE
ETHICS OF THE PLACEBO-CONTROLLED TRIALs
Analyzing the geographical morality problem from the perspectives of in-
ternational relations theory and international law does not simplify the con-
troversy over the ethics of the placebo-controlled trials. This ethical contro-
versy sparks debates within international relations theory and international
law, thus adding new layers to the controversy. But the new layers indicate
that the arguments over the placebo-controlled trails are about more than
interpreting international ethical codes. The ethical arguments implicate
international law and how we think about the way humanity is organized
and should interact.
268. See ICCPR, supra note 143, art. 2(1); ICESCR, supra note 144, art. 2(2).
269. Bayer, supra note 35, at 568.
270. See. e.g., GOSTIN & LAZZARINI, supra note 211, at 87 (arguing that "denying entry to individuals
based solely on HIV infection fundamentally infringes on human rights").
271 See FIDLER, supra note 243, at 206.
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At the heart of the controversy is a political, legal, and moral struggle
about how to deal with the global injustice reflected in the great economic
and health inequities between the developed and developing world. Echoing
revolutionism, opponents of the placebo-controlled trials assert the existence
of a universal ethical and legal framework that can and should be applied
regardless of disparities in wealth among peoples. 272 Defenders of the trials
seem to follow an approach resembling solidaristic rationalism because those
material inequalities between the core and the periphery affect ethical and
legal reasoning. 273 The international relations and international legal analy-
ses in this Article suggest that the universalistic ethical and legal framework
animating opposition to the placebo-controlled trials is not firmly estab-
lished.
The debates over the placebo-controlled trials also tap directly into dis-
course over the post-Cold War ascendance of liberal political and economic
thinking. The revolutionism and solidaristic rationalism seen in the argu-
ments about the placebo-controlled trials are informed by liberalism as both
sides argue from the same liberal-inspired set of international human rights
norms. The debates over the placebo-controlled trials support the arguments
of some that all philosophical and ideological challengers to liberalism have
been vanquished in the world of ideas. 274
The contemporary problem of geographical morality thus differs from the
geographical morality against which Burke protested. Burke's criticism of
Hastings's behavior came at a time when civilizations were only really be-
ginning to clash in earnest. Unlike his contemporaries, Burke thought In-
dian civilization and the Indian peoples morally equal to Europeans and
European civilization. 275 He wanted the two civilizations to co-exist without
one destroying the other.276 Today, the ascendance of liberalism as the global
paradigm has buried concepts of civilizational co-existence. 277 The geo-
graphical morality problem today arises out of deep economic, technologi-
cal, and educational inequalities between rich and poor states rather than
philosophical and cultural dissonance. 278
These material inequalities frustrate both liberal revolutionism and liberal
solidaristic rationalism in the areas of ethics and international law. For both
perspectives, such inequalities are reminders of the superficial nature of lib-
272. See supra Part III.B.3.
273. See supra Part II1.B.2.
274. See Fukuyama, supra note 132, at 3.
275. See FIDLER & WELSH, supra note 88, at 27-28.
276. See Id.
277. See David P. Fidler, A Kinder, Gentler System of Capitulations? International Law, Structural Adjust-
ment Policies, and the Standard of Liberal, Globalized Civilization, 35 TEx. INT'L L.J. 387, 408-11 (2000)
(discussing the rise and dominance of a standard of liberal, globalized civilization in international rela-
tions and international law).
278. But see SAMUEL P. HUNTINGTON, THE CLASH OF CIVILIZATIONS AND THE REMAKING OF
WORLD ORDER (1996) (arguing that this philosophical and cultural dissonance-a clash of civiliza-
tions-will characterize the next phase of international relations).
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eralism's triumph and daunting challenges to physicians, ethicists, lawyers,
and diplomats to deepen human solidarity.
In connection with this goal, the international relations and international
legal analyses in this Article may encourage us to follow one of three paths.
The first path leads us to the conclusion that compromises are inevitable in
international ethics and international law, even in connection with clinical
trial research. Following pluralistic rationalism, we should approximate
ethical standards and concepts of human rights through state interaction
without expecting to achieve them fully on a global scale because of material
inequalities. Such a position counsels against joining the critics of the pla-
cebo-controlled trials. Geographical morality, in other words, remains an
unavoidable feature of international relations.
The second path leads to a re-enforcement of staunch ethical universalism.
Politics and law are inevitably compromised by the sordid state of the
world, but on ethical issues we should maintain a position of no compro-
mise. The ethics of scientists and medical researchers should be held always
to the highest standard. Once scientists and medical researchers begin to act
like diplomats and international lawyers, the ethical slippery slope has been
reached. The application of the international ethical standards should be
animated by the spirit of revolutionism in order to avoid the quagmire of
geographical morality in which the diplomats and international lawyers
wallow. Thus, the placebo-controlled trials should be condemned.
The third path charts a middle way between the resignation of the first
and the zeal of the second. The third path forces us to ask how the problem
of geographical morality can realistically be managed in international rela-
tions. The path leads us to consider utilizing a dynamic version of solidaris-
tic rationalism. The broader and deeper the solidarity between governments
and citizens the better are the prospects of increasing the global application
of international ethical standards and strengthening international legal prin-
ciples. 279 This path is a liberal path because the solidarity it seeks is based on
liberal beliefs, values, and practices. This path is also a homogenizing path
as it seeks to spread liberalism farther and deeper in the international sys-
tem. But it recognizes that ideas and idealism alone do not heal diseases and
feed the hungry. Material inequality forces liberal solidarism to compromise
in the application of ethical norms outside the core in order to make mate-
rial progress against disease in developing countries. The result is geo-
graphical morality.
Universalists would deny, of course, that material inequalities justify
plans of geographical morality. The way to deepen liberalism in interna-
279, See HEDLEY BuLL, THE ANARCHICAL SOCIETY 317 (1977):
The future of international society is likely to be determined, among other things, by the preserva-
tion and extension of a cosmopolitan culture, embracing both common ideas and common values,
and rooted in societies as well as their elites, that can provide the world international society of to-
day with a kind of underpinning enjoyed by the geographically smaller and culturally more homo-
geneous international societies of the past.
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tional relations is not to allow material inequalities to pervert liberal princi-
ples but rather to apply liberal principles universally at all times. Ethical
norms and international human rights will never be universally enjoyed un-
less liberals truly believe they are universally applicable.
The international legal analysis in this Article suggests that the univer-
salist position is too simplistic. Opponents of the placebo-controlled trials
assert that human rights were violated, but when international human
rights law is analyzed, it becomes more difficult to substantiate these asser-
tions. Law and ethics are not synonymous, so the failure to find violations of
international human rights law in the placebo-controlled trials is not
definitive from an ethical point of view. Law is, however, often the real-
world mechanism through which societies make their ethical values and
practices affect human behavior. Presumably international human rights law
enshrines fundamental liberal understandings about protecting human rights.
The international legal analysis thus cannot be dismissed summarily by op-
ponents of the placebo-controlled trials.
The cooperation that occurred between the sponsoring and host govern-
ments and foreign and local researchers in connection with the placebo-
controlled trials might be a model for dynamic solidaristic rationalism in
the world of international clinical trials. The solidaristic core set the basic
parameters guiding the clinical trials, but it was flexible in the face of local
conditions and input from host country researchers and government officials.
The gaping material and health inequalities between the sponsoring and
host countries reveal, however, that dynamic solidarism is needed in many
more areas than simply clinical trials.280
Laments are frequently heard about the failure of the rich, Western coun-
tries adequately to support developing countries struggling under the enor-
mous burden that HIV/AIDS and other infectious diseases are imposing on
them.2 81 This immediately raises the accusation against the placebo-
controlled trials that any successful drug regimens that resulted from them
would not be available to developing countries' populations because of their
expense. Supporters of the placebo-controlled trials have no good response to
this accusation other than emphasizing the primary need to develop new
therapies before worrying about their cost or potential availability. People
living in developing countries are justified in viewing such arguments with
a skeptical eye. The behavior of the United States toward South Africa in
connection with the latter's desire to increase access to HIV therapies
through compulsory licensing stands as evidence of U.S. arrogance and in-
280. See, e.g., Amir Attaran, Human Rights and Biomedical Research Funding for the Developing World:
Discovering State Obligations tinder the Right to Health, 4 HEALTi & Hum. RTs. 27 (1999) (arguing that
developed countries' failure to allocate more public funds for research on diseases of fundamental concern
to developing countries involve "ubiquitous and grievous violations of international law").
281. See, eg., Amir Attaran & Jeffrey Sachs, Defining and Refining International Donor Support for Comn-
bating the AIDS Pandemic, 357 THE LANCET 57 (2001) (arguing that the international aid effort against
HIV/AIDS is greatly incommensurate with the severity of the pandemic).
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difference about Africa's public health problems. Why is it plausible that
new therapies developed through placebo-controlled trials will be any more
available to developing countries' populations than the therapies that cur-
rently exist?
More broadly, the ethical dispute over the placebo-controlled trials con-
nects with criticisms of the West's general indifference toward the problems
of developing countries, particularly those in sub-Saharan Africa. The re-
sponse from the West and international organizations to the scale of the
HIV/AIDS crisis has been severely criticized as inadequate. 282 The indiffer-
ence is manifest, however, outside the HIV/AIDS context. How developing
countries' governments are roughly handled by the World Bank and Inter-
national Monetary Fund through structural adjustment policies has been the
subject of intense criticism. 283 The United Nations' failure to intervene in
the genocide that took place in Rwanda serves as a symbol of the weakness
of contemporary liberal solidarism with respect to Africa. 284 Historically, the
aftermath of colonial and imperial exploitation of developing countries by
the West is still being felt today.
These observations mean that debates over the placebo-controlled trials
have to be put into perspective with the larger relationship between devel-
oping countries and the West. Solidaristic rationalism's preference for ethical
flexibility and a local standard of care in connection with international clini-
cal trials as a way to deepen solidarity between the core and periphery is a
gamble that, against the depressing context of the core's general attitude and
policies toward developing countries, should be feared rather than embraced.
The gamble will only be justified when clinical trials organized under
plans of geographical morality produce drugs that the West makes afforda-
bly available to developing countries. Nothing in the defense of the placebo-
controlled trials even hints at a sustainable plan to improve developing
countries' access to new drugs developed through international clinical re-
search. This is a glaring problem given the terrible obstacles that confront
increasing access to drugs in developing countries. 28 5 Absent a sustainable
plan for access to new drugs, liberal solidarism's gamble in the placebo-
controlled trials may quickly resemble past Western exploitation of devel-
oping countries. Echoing Burke, we must ask what liberal solidarism's gam-
ble with geographical morality will leave inhabitants of developing coun-
tries in the way of scientific advances against disease.
282. See, eg., id.
283. See Fidler, supra note 277, at 388 (describing criticisms of structural adjustment policies of the
World Bank and International Monetary Fund).
284. See Letter from Kofi A. Annan, Secretary-General, United Nations, to the President of the Secu-
rity Council, Annex: Report of the Independent Inquiry into the Actions of the United Nations During the 1994
Genocide in Ruanda, U.N. SCOR, at 3-59, U.N. Doc. S11999/1257 (1999), http://www.un.org/News/
ossg/rwandareport.htm (visited Apr. 22, 2001).
285. See B. P~coul et al., Access to Essential Drugs in Poor Countries: A Lost Battle?, 281 JAMA 361
(1999).
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Moving in an ethical and legal direction toward a local standard of care in
international clinical trials brings liberal solidarism closer to pluralistic ra-
tionalism and realism in accepting or exploiting a plan of geographical mo-
rality. In this plan, the moral and international legal duties of governments
and medical and scientific researchers are not governed by liberal principles,
but climates, degrees of longitude and latitude, and socio-economic ine-
qualities-parallels not of human dignity, but of geography and poverty.
When we have crossed these parallels, liberal principles shrink in the face of
human suffering and we commence an old order and system of things based
on exploitation and raison d'6tat disguised in the enigmatic, liberal garb of
globalization.
